0002. The invention relates to the field of cell based or regenerative therapy for lung disorders, diseases and injuries.
BACKGROUND OF THE INVENTION
0003 Various publications, including patents, published applications and technical articles are cited throughout the specification. Each of these cited publications is incorporated by reference herein, in its entirety. 0004 Lung disease, both chronic and acute, remains a significant cause of morbidity and mortality throughout the world. Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the world (Spurzem and Rennard, Semin Respir Crit Care Med, 2005; 26: 142-153) and can be caused by anatomic narrowing of the airways or blocking of airways with mucus that interferes with normal breathing. Additionally, interstitial lung disease, also known as pulmonary fibrosis, is classified as a restrictive disease that includes a variety of chronic lung disorders. Management of chronic lung disease includes drug therapy, oxygen therapy, Surgery, and pulmonary rehabilitation. 0005 While 90% of COPD patients are smokers, only 10% of Smokers develop the disease, Suggesting that genetic predisposition may be an important prognostic factor. (Siafa kas and Tzortzaki, Respir Med, 2002 August; 96(8): 615-24 ).
Smoker's lung disease is characterized by chronic active inflammation, airway mucus hypersecretion, and emphysema (MacNee, Proc Am Thorac Soc., 2005; 2(4): 258-66; discus sion 290-1) and is only partially reversible upon cessation of smoking (Spurzem and Rennard, Semin Respir Crit Care Med, 2005; 26: 142-153) . Inflammation of the airways and lung parenchyma plays a major role in the pathogenesis of chronic obstructive pulmonary disease. Cigarette Smoke has been shown to induce pulmonary inflammation and ulti mately lead to COPD even if exposure to the cigarette smoke has stopped. 0006 Emphysema is one of the major factors determining morbidity and mortality in chronic obstructive pulmonary diseases. This disease is characterized, for example, by loss of elasticity of the lung tissue, from destruction of structures Supporting the lung tissues such as alveoli, and destruction of capillaries feeding the alveoli. This destruction can be caused by inflammatory enzymes, for example elastin. Emphysema is defined as the enlargement of peripheral air space in the lung (including respiratory bronchioles and alveoli), which is accompanied by the destruction of alveolar wall structures. The incidence of patients with emphysema has increased in the past decades as a result of the increase in environmental pollutants, cigarette Smoking, and other exposure to noxious Substances. The current standard of care today demonstrates that only lung transplantation can provide remediation for severe emphysema. There remains a need for an adequate and useful approach to treat, repair and/or ameliorate lung dam age in patients with emphysema, Such as elastase-induced emphysema. 0007 Animal models exposed to cigarette smoke have been studied to investigate the pathology and the efficacy of various therapeutic interventions. Unfortunately, these stud ies have only demonstrated limited success. Part of the prob lem is that commonly used rat and mouse strains show only mild inflammation and mucus secretion in response to ciga rette Smoke. (Guerassimov, A. et al., Am J Respir Crit Med, 2004 Nov. 1; 170(9): 974-80. Epub 2004 Jul. 28) . and the corresponding injuries are rapidly reversible. Healthy labo ratory rodents may therefore possess an extraordinary ability to compensate and regenerate lung function following an injury, which may underlie their relative resistance to devel oping COPD. It has recently been shown that the genetically predisposed spontaneous hypersensitive (SH) rats display phenotypes (e.g., systemic inflammation, hypercoagulation, oxidative stress, and Suppressed immune function) that are also found in COPD patients. (Yu, B, et al., Inhal Toxicol, 2008 May; 2007): 623-33) . Therefore, the SH rat model may offer a more relevant model of experimental COPD. 0008 Restrictive lung disease is one of the most common causes of morbidity and mortality and has three primary etiologies, lung cancer, pneumonia and pulmonary fibrosis. Idiopathic pulmonary fibrosis (IPF) is a crippling disease characterized by progressive dyspnea and is associated with a high mortality rate, progressive fixed tissue fibrosis, architec tural distortion, and loss of function. (Ortiz, LA, et al., Proc Natl Acad Sci USA., 2003 Jul. 8, 2003 : 8407-11. Epub 2003 Jun. 18 ). An excess of profibrotic cytokines or a deficiency in antifibrotic cytokines has been implicated in the pathologic process. In the United States, prevalence estimates for idiopathic pulmonary fibrosis vary from three to six cases per one hundred thousand people. Presently, no effective therapies to reverse or retard the course of the disease are available. Most treatments, such as corticosteroids, immuno Suppressive, immunomodulatory, or antifibrotic agents, seek to suppress inflammation, but none has been proven to alter IPF disease progression. Therefore, a significant need exists for the development of novel therapies aimed at slowing or halting fibrosis while enhancing endogenous lung repair and regeneration. 0009. It has been shown that mesenchymal stem cells (MSCs) can differentiate into alveolar epithelial cells in injured lungs of mice injured with bleomycin (BLM), and the engraftment of MSCs may suppress inflammation and depo sition of collagen in damaged lung tissue. (Zhao, F, et al., Transplant Proceedings, 2008 June; 40(5) :1700-1705: Ortiz, LA, et al., Proc Natl AcadSci USA., 2003 Jul. 8, 2003 (14): 8407-11, Epub 2003 Jun. 18; Rojas et al., Am J Respir Cell Mol Biol, 2005:33:145) . BLM is a cytostatic antibiotic with antitumor activity and is a well-recognized compound to study pulmonary fibrosis in animal models. It induces alveo lar epithelial cell injury and inflammation in the lung, leading to pulmonary fibrosis. 0010 Acute lung injury (ALI) and acute respiratory dis tress syndrome (ARDS) also continue to be significant causes of morbidity and mortality in the intensive care setting. ALI and ARDS are serious diseases characterized by the abrupt onset of hypoxemia with diffuse pulmonary edema in response to either direct injury (e.g., drowning, pneumonia, inhaled toxic gases, and pulmonary contusion) or indirect injury (e.g., severe sepsis, transfusion, shock, and pancreati tis). ALI and ARDS are currently treated by mechanical ven tilation and Supportive care. 0011 Cell therapy is one of the most exciting fields in translational medicine and is developing into a new therapeu tic platform to treat a vastarray of clinical disorders. Over the past five years, the field of cell therapies in lung diseases has continued to grow rapidly. Several studies have demonstrated the feasibility of employing cell therapy to treat lung disease. For example, circulating endothelial progenitor cells (EPCs) may contribute to regeneration of diseased pulmonary vascu lature and are being investigated in patients with pulmonary hypertension. (Diller, G. P. et al., Circulation, 2008 Jun. 10, 117(23) reconstituting a target tissue, thereby restoring physiologic and anatomic functionality. The application of stem cell tech nology is wide-ranging, including tissue engineering, gene therapy delivery, and cell therapeutics, i.e., delivery of bio therapeutic agents to a target location via exogenously Sup plied living cells or cellular components that produce or con tain those agents. The identification of stem cells has stimulated research aimed at the selective generation of spe cific cell types for regenerative medicine. 0013. A reliable, well-characterized and plentiful supply of substantially homogenous populations of such cells having the ability to differentiate into an array of lung tissue, includ ing vascular structures, would be an advantage in a variety of diagnostic and therapeutic applications for lung repair, regen eration, protection and improvement, and for improvement of blood flow and oxygen/CO exchange before, during or Sub sequent to lung damage due to lung diseases, disorders, and/ or injuries.
SUMMARY OF THE INVENTION
0014. One aspect of the invention features methods of treating a patient having lung disease, disorders, and/or inju ries. Such diseases, disorders, and/or injuries include, but are not limited to, chronic obstructive pulmonary diseases (COPD), pulmonary fibrosis, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), and the damages associated thereto.
0015. One aspect of the invention features a method of treating a patient having lung disease, disorder and/or injury, the method comprising administering to the patient umbilical cord tissue-derived cells in an amount effective to treat the lung disease, disorder and/or injury, and damage associated therewith.
0016. In a particular embodiment, the lung disease, disor der, and/or injury is obstructive, restrictive, and/or caused from injuries such as those associated with or leading to ALI and/or ARDS. In certain embodiments, the cells are induced 0018. In other embodiments, the cells are administered with at least one other agent, which may be an antithrombo genic agent, an anti-inflammatory agent, an immunosuppres sive agent, an immunomodulatory agent, pro-angiogenic, or an antiapoptotic agent, for example. The other agent can be administered simultaneously with, before or after the umbili cal cord tissue-derived cells.
0019. The cells are preferably administered at or proximal to the sites of the lung disease, disorder, and/or injury, but can also be administered at locations distal to Such sites. They can be administered by injection, infusion, a device implanted in the patient, or by implantation of a matrix or scaffold con taining the cells. The cells may exert a trophic effect, such as proliferation, on the lung tissue of the patient. The cells may induce migration of lung tissue cells, for example vascular Smooth muscle cells, vascular endothelial cells, lung progeni tor cells, pericytes, vascular Smooth muscle progenitor cells, or vascular endothelium progenitor cells to the site or sites of lung disease, disorder, and/or injury. 0020. Another aspect of the invention features pharmaceu tical compositions and kits for treating a patient having a lung disease, disorder, and/or injury, comprising a pharmaceuti cally acceptable carrier, diluent, and/or buffer, and the umbili cal cord-tissue derived cells or preparations made from Such umbilical cord-tissue derived cells. In some preferred embodiments, the preparations comprise FGF and HGF. The pharmaceutical compositions and kits are designed and/or formulated for practicing the methods of the invention as outlined above.
0021. According to another aspect of the invention, the above-described methods may be practiced using a prepara tion made from the umbilical cord tissue-derived cells, wherein the preparation comprises a cell lysate of the umbili cal cord tissue-derived cells, an extracellular matrix of the umbilical cord tissue-derived cells or a conditioned medium in which the umbilical cord tissue-derived cells were grown. It is preferred that such preparations comprise FGF and HGF. Another aspect of the invention involves practicing the inven tion with products of the umbilical cord tissue-derived cells, e.g., trophic factors. 0022. Other aspects of the invention feature pharmaceuti cal compositions and kits containing preparations comprising cell lysates, extracellular matrices or conditioned media of the umbilical cord tissue-derived cells. The compositions may also comprise a pharmaceutically acceptable carrier, diluent, and/or buffer, as known in the art. Other aspects of the invention feature treatment with pharmaceutical composi tions and kits comprising products of the umbilical cord tis sue-derived cells.
0023. Other features and advantages of the invention will be understood by reference to the detailed description and examples that follow.
BRIEF DESCRIPTION OF THE DRAWINGS 0024 FIG. 1 shows the BALE total protein concentration: Total protein was measured using a Pierce BCA Protein Assay. Each data point represents measurements obtained from a single animal. The horizontal lines represent the aver age of all measurements. Student T-test analysis was pre formed. The data is shown in tabular form below (Table 8) . 0025 FIG. 2a shows a Cytokine/Chemokine Analysis of Lung Homogenate: The concentrations of twenty-two differ ent cytokines/chemokines were determined for lung homo genate using a mouse 22-multiplex bead kit (Millipore) fol lowing the manufacturer's protocol and analyzed using the BioRad Bioplex machine. Databars represent the mean of six samples. The data is shown in tabular form below (FIG. 3) . 0026 FIG. 2b shows a Cytokine/Chemokine Analysis of BALE: The concentrations of twenty-two different cytok ines/chemokines were determined for BALF using a mouse 22-multiplex bead kit (Millipore) following the manufactur er's protocol and analyzed using the BioRad Bioplex machine. Data bars represent the mean of six samples. Data shown in tabular form below (FIG. 4) . 0027 FIG. 3 shows a lung Homogenate Cytokine/ Chemokine Analysis: The concentrations of twenty-two dif ferent cytokines/chemokines were determined for lung homogenate using a mouse 22-multiplex bead kit (Millipore) following the manufacturer's protocol and analyzed using the BioRad Bioplex machine. 0028 FIG. 4 shows a BALE Cytokine/Chemokine Analy sis: The concentrations of twenty-two different cytokines/ chemokines were determined for BALF using a mouse 22-multiplex bead kit (Millipore) following the manufactur er's protocol and analyzed using the BioRad Bioplex machine.
DETAILED DESCRIPTION
0029. In the following detailed description of the illustra tive embodiments, reference is made to the accompanying drawings that form a part hereof. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is understood that other embodiments may be utilized and that logical structural, mechanical, electrical, and chemical changes may be made without departing from the spirit or scope of the invention. To avoid detail not necessary to enable those skilled in the art to practice the embodiments described herein, the description may omit certain information known to those skilled in the art. The following detailed description is, therefore, not to be taken in a limiting sense. 0030 Various terms are used throughout the specification and claims. Such terms are to be given their ordinary meaning in the art unless otherwise indicated. Other specifically defined terms are to be construed in a manner consistent with the definition provided herein. 0031 "Lung tissue' can include, but is not limited to, all lung tissue structures and associated tissues, including, but not limited to, Veins, arteries, vessels, capillaries, and cells of the type that are part of, or associated with, Such structures; lung and pleaural tissue; and vascular Smooth muscle, peri cyte, and vascular endothelial lineages and/or phenotypes.
0032. As used herein, "respiratory or lung diseases, disor ders and injuries' include, but are not limited to, obstructive lung diseases, restrictive lung diseases, respiratory tract infections (upper and lower), respiratory tumors, pleural cav ity diseases, and pulmonary vascular diseases. The damage to lung tissue caused by these diseases, disorders and/or injuries can be characterized as lung damage within the scope of the present invention. Furthermore, the damaged lung tissue encompassed by the invention includes all lung tissue struc tures and associated tissues, including, veins, arteries, ves sels, capillaries, and cells of the type that are part of, or associated with, such structures. "Obstructive lung diseases" can include COPD, cystic fibrosis, bronchiectasis, bronchi olitis, emphysema and allergic bronchopulmonary aspergillosis. COPD, for example, is caused by noxious par ticles orgases (most commonly from Smoking), which trigger an abnormal inflammatory response in the lung. The inflam matory response in the larger airways is known as chronic bronchitis, which is diagnosed clinically when people regu larly cough up sputum. In the alveoli, the inflammatory response causes destruction of the tissue of the lung, a process known as emphysema. It should be realized that these issues are those associated with COPD as it pertains to the instant invention. The etiology of COPD includes, but is not limited to, tobacco Smoking, occupational exposures to workplace dusts (e.g., coal mining, gold mining, the cotton textile indus try and chemical industry), air pollution, and genetics. 0033 "Restrictive lung diseases, as used herein, are also known as interstitial lung diseases (ILDs). Many of these are idiopathic. Examples include: idiopathic pulmonary fibrosis, idiopathic interstitial pneumonia (several types), Sarcoidosis, eosinophilic pneumonia, lymphangioleiomyomatosis, pull monary Langerhan's cell histiocytosis, and pulmonary alveo lar proteinosis. ILDs affect the interstitium of the lung: alveo lar epithelium, pulmonary capillary endothelium, basement membrane, perivascular and perilymphatic tissues. Most types of ILDs involve fibrosis. 0034 Respiratory tumors include both malignant and benign tumors. Malignant tumors include, for example, Small cell lung cancer, non-Small cell lung cancer (adenocarci noma, squamous cell carcinoma, and large cell undifferenti ated carcinoma), lymphoma, as well as other cancers. Benign tumors are rare but can include pulmonary hamartoma and congenital malformations, for example. 0035. As used herein, "acute lung injury" (ALI) is a dif fuse heterogeneous lung injury characterized by hypoxemia, non-cardiogenic pulmonary edema, low lung compliance and widespread capillary leakage. ALI is caused by any stimulus of local or systemic inflammation. Acute respiratory distress syndrome (ARDS) is more severe than ALI. As used herein, ALI and ARDS can be characterized by abrupt onset of hypoxemia with diffuse pulmonary edema in response to either direct injury or indirect injury. As used herein, "direct injury includes, but is not limited to, lung injuries Stemming from drowning episodes, pneumonia, inhaled toxic gases, and pulmonary contusions. As used herein, "indirect injury' can be from severe sepsis, transfusion, shock, and pancreatitis, for example. These injuries that lead to ALI and ARDS result in disruption of the alveolar-capillary interface, leakage of pro tein rich fluid into the interstitium and alveolar space, exten sive release of cytokines, and migration of neutrophils. 0036. The lung diseases, disorders and injuries encom passed by the methods of the present invention are known in the art. The characteristics of each, including associated com plications, etiologies, and treatments, are known by those of skill in the art. This includes lung diseases, disorders and injuries not specifically discussed herein, as they would apply to obstructive and restrictive lung diseases, disorders and injuries. 0037. The cells used in the present invention are generally referred to as postpartum cells or postpartum-derived cells (PPDCs). The cells are more specifically "umbilicus-derived cells" or "umbilical cord-derived cells" (UDC), or "umbilical cord tissue-derived cells' (UTC). In addition, the cells may be described as being stem or progenitor cells, the latter term being used in the broad sense. The term "derived' is used to indicate that the cells have been obtained from their biologi cal Source and grown or otherwise manipulated in vitro (e.g., cultured in a growth medium to expand the population and/or to produce a cell line). The in vitromanipulations of umbilical stem cells and the unique features of the umbilicus-derived cells of the present invention are described in detail below. 0038 Stem cells are undifferentiated cells defined by the ability of a single cell both to self-renew, and to differentiate to produce progeny cells, including self-renewing progeni tors, non-renewing progenitors, and terminally differentiated cells. Stem cells are also characterized by their ability to differentiate in vitro into functional cells of various cell lin eages from multiple germ layers (endoderm, mesoderm and ectoderm), as well as to give rise to tissues of multiple germ layers following transplantation, and to contribute Substan tially to most, if not all, tissues following injection into blas tocysts.
0039 Stem cells are classified according to their develop mental potential as: (1) totipotent; (2) pluripotent; (3) multi potent; (4) oligopotent; and (5) unipotent. Totipotent cells are able to give rise to all embryonic and extraembryonic cell types. Pluripotent cells are able to give rise to all embryonic cell types. Multipotent cells include those able to give rise to a Subset of cell lineages, but all within a particular tissue, organ, or physiological system. For example, hematopoietic stem cells (HSC) can produce progeny that include HSC (self-renewal), blood cell-restricted oligopotent progenitors, and all cell types and elements (e.g., platelets) that are normal components of the blood. Cells that are oligopotent can give rise to a more restricted Subset of cell lineages than multipo tent stem cells. Cells that are unipotent are able to give rise to a single cell lineage (e.g., spermatogenic stem cells). 0040 Stem cells are also categorized on the basis of the source from which they are obtained. An adult stem cell is generally a multipotent undifferentiated cell found in tissue comprising multiple differentiated cell types. The adult stem cell can renew itself. Under normal circumstances, it can also differentiate to yield the specialized cell types of the tissue from which it originated, and possibly other tissue types. An embryonic stem cell is a pluripotent cell from the inner cell mass of a blastocyst-stage embryo. A fetal stem cell is one that originates from fetal tissues or membranes. A postpartum stem cell is a multipotent or pluripotent cell that originates substantially from extraembryonic tissue available after birth, namely, the umbilical cord. These cells have been found to possess features characteristic of pluripotent stem cells, including rapid proliferation and the potential for differentia tion into many cell lineages. Postpartum stem cells may be blood-derived (e.g., as are those obtained from umbilical cord blood) or non-blood-derived (e.g., as obtained from the non blood tissues of the umbilical cord and placenta).
0041 Various terms are used to describe cells in culture. "Cell culture" refers generally to cells taken from a living organism and grown under controlled conditions (in culture' or "cultured). A "primary cell culture' is a culture of cells, tissues, or organs taken directly from an organism(s) before the first subculture. Cells are "expanded in culture when they are placed in a growth medium under conditions that facilitate cell growth and/or division, resulting in a larger population of the cells. When cells are expanded in culture, the rate of cell proliferation is sometimes measured by the amount of time needed for the cells to double in number. This is referred to as "doubling time." 0042. The term "cell line generally refers to a population of cells formed by one or more subcultivations of a primary cell culture. Each round of subculturing is referred to as a passage. When cells are subcultured, they are referred to as having been "passaged. A specific population of cells, or a cell line, is sometimes referred to or characterized by the number of times it has been passaged. For example, a cultured cell population that has been passaged ten times may be referred to as a P10 culture. The primary culture, i.e., the first culture following the isolation of cells from tissue, is desig nated P0. Following the first subculture, the cells are described as a secondary culture (P1 or passage 1). After the second subculture, the cells become a tertiary culture (P2 or passage 2), and so on. It will be understood by those of skill in the art that there may be many population doublings during the period of passaging; therefore the number of population doublings of a culture is greater than the passage number. The expansion of cells (i.e., the number of population doublings) during the period between passaging depends on many fac tors, including, but not limited to, the seeding density, Sub strate, medium, growth conditions, and time between passag 1ng 0043 "Differentiation' is the process by which an unspe cialized ("uncommitted') or less specialized cell acquires the features of a specialized cell. Such as a nerve cell or a muscle cell, for example. A "differentiated cell is one that has taken on a more specialized ("committed') position within the lin eage of a cell. The term "committed, when applied to the process of differentiation, refers to a cell that has proceeded in the differentiation pathway to a point where, under normal circumstances, it will continue to differentiate into a specific cell type or Subset of cell types, and cannot, under normal circumstances, differentiate into a different cell type or revert to a less differentiated cell type. "De-differentiation" refers to the process by which a cell reverts to a less specialized (or committed) position within the lineage of a cell. As used herein, the "lineage' of a cell defines the heredity of the cell, i.e., which cells it came from and what cells it can give rise to. The lineage of a cell places the cell within a hereditary scheme of development and differentiation. 0044. In a broad sense, a "progenitor cell' is a cell that has the capacity to create progeny that are more differentiated than itself, and yet retains the capacity to replenish the pool of progenitors. By that definition, stem cells themselves are also progenitor cells, as are the more immediate precursors to terminally differentiated cells. When referring to the cells of the present invention, as described in greater detail below, this broad definition of progenitor cell may be used. In a narrower sense, a progenitor cell is often defined as a cell that is inter mediate in the differentiation pathway, i.e., it arises from a stem cell and is intermediate in the production of a mature cell type or subset of cell types. This type of progenitor cell is generally not able to self-renew. Accordingly, if this type of cell is referred to herein, it will be referred to as a "non renewing progenitor cell'orasan "intermediate progenitor or precursor cell." 0045. Several terms are used herein with respect to cell or tissue transplantation; or cell replacement therapy. The terms "autologous transfer," "autologous transplantation." "autograft' and the like refer to treatments wherein the cell or transplant donor is also the cell or transplant recipient. The terms "allogeneic transfer," "allogeneic transplantation." "allograft' and the like refer to treatments wherein the cellor transplant donor is of the same species as the recipient, but is not the same individual. A cell transfer in which the donor's cells have been histocompatibly matched with a recipient is sometimes referred to as a "syngeneic transfer." The terms "Xenogeneic transfer. "Xenogeneic transplantation." "xenograft' and the like refer to transplantation wherein the cell or transplant donor is of a different species than the recipient. 0046. The terms "pharmaceutically acceptable carrier' or "pharmaceutically acceptable medium' which may be used interchangeably with the terms "biologically compatible car rier' or "biologically compatible medium' generally refer to reagents, cells, compounds, materials, compositions, and/or dosage forms that are not only compatible with the cells and other agents to be administered therapeutically, but also are, Suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other complication commensurate with a reason able benefit/risk ratio. As described in greater detail herein, pharmaceutically acceptable carriers Suitable for use in the present invention include liquids, semi-solid (e.g., gels) and Solid materials (e.g., cell scaffolds and matrices, tubes, sheets and other Such materials known in the art and described in greater detail herein). These semi-solid and solid materials may be designed to resist degradation within the body (non biodegradable) or they may be designed to degrade within the body (biodegradable, bioerodable). A biodegradable material may further be bioresorbable or bioabsorbable, i.e., it may be dissolved and absorbed into bodily fluids (water-soluble implants are one example), or degraded and ultimately elimi nated from the body, either by conversion into other materials or breakdown and elimination through natural pathways. The biodegradation rate can vary according to the desired release rate once implanted in the body. 0047. A "conditioned medium' is a medium in which a specific cell or population of cells has been cultured, and then removed. When cells are cultured in a medium, they may secrete cellular factors that can provide trophic Support to other cells. Such trophic factors include, but are not limited to, hormones, cytokines, extracellular matrix (ECM), proteins, vesicles, antibodies, and granules. The medium containing the cellular factors is the conditioned medium.
0048 Generally, a "trophic factor" is defined as a sub stance that promotes Survival, growth, proliferation and/or maturation of a cell, or stimulates increased activity of a cell. 0049. As used herein, the term "growth medium' gener ally refers to a medium sufficient for the culturing of postpar tum-derived cells. In particular, one presently preferred medium for the culturing of the cells of the invention com prises Dulbecco's Modified Essential Media (DMEM). Par ticularly preferred is DMEM-low glucose (DMEM-LG) (In vitrogen, Carlsbad, Calif.). The DMEM-LG is preferably supplemented with serum, most preferably fetal bovine Jun. 24, 2010 serum or human serum. Typically, 15% (v/v) fetal bovine serum (e.g. defined fetal bovine serum, Hyclone, Logan Utah) is added, along with antibiotics/antimycotics (prefer ably 100 Unit/milliliter penicillin, 100 milligrams/milliliter streptomycin, and 0.25 microgram/milliliter amphotericin B; (Invitrogen, Carlsbad, Calif.)), and 0.001% (v/v) 2-mercap toethanol (Sigma, St. Louis Mo.) . In some cases different growth media are used or different Supplementations are pro vided, and these are normally indicated in the text as Supple mentations to growth medium. In certain chemically-defined media the cells may be grown without serum present at all. In Such cases, the cells may require certain growth factors, which can be added to the medium to Support and Sustain the cells. Presently preferred factors to be added for growth in serum-free media include one or more of bFGF, EGF, IGF-I, and PDGF. In more preferred embodiments, two, three or all four of the factors are added to serum free or chemically defined media. In other embodiments, LIF is added to serum free medium to support or improve growth of the cells. 0050. The term "standard growth conditions, as used herein refers to culturing of cells at 37° C., in a standard atmosphere comprising 5% CO and relative humidity main tained at about 100%. While the foregoing conditions are useful for culturing, it is to be understood that such conditions are capable of being varied by the skilled artisan who will appreciate the options available in the art for culturing cells. 0051. The term "effective amount" refers to a concentra tion or amount of a compound, material, or composition, as described herein, that is effective to achieve a particular bio logical result. Such results include, but are not limited to, the regeneration, repair, or improvement of skeletal tissue, the improvement of blood flow, and/or the stimulation and/or the Support of angiogenesis in patients with lung damage from those diseases, disorders and injuries within the scope of this invention. Such effective activity may be achieved, for example, by administering the cells and/or compositions of the present invention to patients with lung damage as described herein. With respect to the administration of UTC to a patient in Vivo, an effective amount may range from as few as several hundred or fewer, to as many as several million or more. In specific embodiments, an effective amount may range from about 10 to about 10' cells more specifically, at least about 10 cells. It will be appreciated that the number of cells to be administered will vary depending on the specifics of the lung disease, disorder or injury to be treated, including but not limited to the size or total volume? surface area to be treated, and the proximity of the site of administration to the location of the region to be treated, among other factors familiar to the medicinal biologist. 0052. The terms "treat," "treating" or "treatment" refer to any success or indicia of Success in the attenuation or ame lioration of an injury, pathology or condition, including any objective or Subjective parameter Such as abatement, remis Sion, diminishing of symptoms or making the injury, pathol ogy, or condition more tolerable to the patient, slowing in the rate of degeneration or decline, making the final point of degeneration less debilitating, improving a Subject's physical or mental well-being, or prolonging the length of Survival. The treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, or neurological examination. 0053. The terms "effective period," "effective period of time' or "effective conditions' refer generally to a period of time or other controllable conditions (e.g., temperature, humidity for in vitro methods) necessary or preferred for an agent or pharmaceutical composition to achieve its intended result.
0054) The terms "individual," "patient" or "subject" are used interchangeably herein, and refer to animals, preferably mammals, and more preferably humans, who are treated with the pharmaceutical or therapeutic compositions or in accor dance with the methods described herein.
0055. The term "matrix" as used herein generally refers to biodegradable and/or bioresorbable materials that are admin istered with the cells to a patient. The matrix may act as a temporary scaffold until replaced by newly grown cells. Such as, skeletal muscle, pericytes, vascular Smooth muscle, or vascular endothelial tissue. In some embodiments, the matrix may provide for the sustained release of trophic factures or other agents used in conjunction with the cells and may pro vide a structure for developing tissue growth in the patient. In other embodiments, the matrix simply provides a temporary scaffold for the developing tissue. The matrix can be in par ticulate form (macroparticles greater than 10 microns in diameter or microparticles less than 10 microns in diameter), or it can be in the form of a structurally stable, three-dimen sional implant (e.g., a scaffold). The matrix can be a slurry, hydrogel or a three-dimensional structure Such as a cube, cylinder, tube, block, film, sheet oran appropriate anatomical form.
0056. The term "scaffold' as used herein generally refers to a three dimensional porous structure that provides a tem plate for cell growth. A scaffold is made of biodegradable and/or bioresorbable materials that degrade over time within the body. The length of time taken for the scaffold to degrade may depend upon the molecular weight of the materials. Thus, higher molecular weight material may result in poly mer scaffolds which retain their structural integrity for longer periods of time; while lower molecular weights result in both slower release and shorter scaffold lives. The scaffold may be made by any means known in the art. Examples of polymers which can be used to form the scaffold include natural and synthetic polymers. 0057 The term "isolate" as used herein generally refers to a cell which has been separated from its natural environment. This term includes gross physical separation from its natural environment, e.g., removal from the donor animal. In pre ferred embodiments, an isolated cell is not present in a tissue, i.e., the cell is separated or dissociated from the neighboring cells with which it is normally in contact. Preferably, cells are administered as a cell Suspension. As used herein, the phrase "cell suspension' includes cells which are in contact with a medium and which have been dissociated, e.g., by Subjecting a piece of tissue to gentle trituration. 0.058. In its various embodiments described herein, the present invention features methods and pharmaceutical com positions for treatment of lung diseases, disorders and/or injuries that utilize progenitor cells and cell populations derived from postpartum tissues, umbilicus tissue in particu lar. These methods and pharmaceutical compositions are designed to stimulate and Support angiogenesis, to improve blood flow, to regenerate, repair, and improve lung tissue damaged by a lung disease, disorder and/or injury, and/or to protect the lung tissue from Such diseases, disorders and/or injuries. The cells, cell populations and preparations compris ing cell lysates, conditioned media and the like, used in the pharmaceutical preparations and methods of the present 0060) Isolation of the UTC preferably occurs in an aseptic environment. The umbilical cord may be separated from the placenta by means known in the art. Blood and debris are preferably removed from the postpartum tissue prior to iso lation of the UTC. For example, the postpartum tissue may be washed with buffer solution, including but not limited to phosphate buffered saline. The wash buffer also may com prise one or more antimycotic and/or antibiotic agents, including but not limited to penicillin, Streptomycin, ampho tericin B. gentamicin, and nystatin. 0061 Postpartum tissue comprising an umbilical cord, or a fragment or section thereof, is preferably disaggregated by mechanical force (mincing or shear forces). In a presently preferred embodiment, the isolation procedure also utilizes an enzymatic digestion process. Many enzymes are known in the art to be useful for the isolation of individual cells from complex tissue matrices to facilitate growth in culture. Diges tion enzymes range from weakly digestive (e.g. deoxyribo nucleases and the neutral protease, dispase) to strongly diges tive (e.g. papain and trypsin), and are available commercially. A non-exhaustive list of Such enzymes includes mucolytic enzyme activities, metalloproteases, neutral proteases, serine proteases (such as trypsin, chymotrypsin, or elastase), and deoxyribonucleases. Presently preferred are enzyme activi ties selected from metalloproteases, neutral proteases and mucolytic activities. For example, collagenases are known to be useful for isolating various cells from tissues. Deoxyribo nucleases can digest single-stranded DNA and can minimize cell-clumping during isolation. Preferred methods involve enzymatic treatment with collagenase and dispase, or colla genase, dispase, and hyaluronidase. The skilled artisan will appreciate that many Such enzyme treatments are known in the art for isolating cells from various tissue sources, and is well-equipped to assess new or additional enzymes or enzyme combinations for their utility in isolating the cells of the invention. Preferred enzyme treatments can be from about 0.5 to 2 hours long or longer. In other preferred embodiments, the tissue is incubated at about 37° C. during the enzyme treatment of the dissociation step. (Mediatch, Inc., Herndon, Va.) . The culture medium may be Supplemented with one or more components includ ing, for example, fetal bovine serum (FBS), preferably about 2-15% (v/v); equine serum (ES); human serum (HS); beta mercaptoethanol (BME or 2-ME), preferably about 0.001% (V/v); one or more growth factors, for example, platelet-de rived growth factor (PDGF), epidermal growth factor (EGF), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), insulin-like growth factor-1 (IGF-1), leuko cyte inhibitory factor (LIF) and erythropoietin (EPO); amino acids, including L-valine; and one or more antibiotic and/or antimycotic agents to control microbial contamination, Such as penicillin G, Streptomycin Sulfate, amphotericin B. gen tamicin, and nystatin, either alone or in combination. The culture medium preferably comprises growth medium (e.g., DMF-M-low glucose, serum, BME and an antibiotic agent). 0063. The cells are seeded in culture vessels at a density to allow cell growth. In a preferred embodiment, the cells are cultured at about 0 to about 5 percent by volume CO, in air. In some preferred embodiments, the cells are cultured at about 2 to about 25 percent O, in air, preferably about 5 to about 20 percent O in air. The cells preferably are cultured at a tem perature of about 25 to about 40° C. and more preferably are cultured at 37° C. The cells are preferably cultured in an incubator. The medium in the culture vessel can be static or agitated, for example, using a bioreactor. The UTC is prefer ably grown under low oxidative stress (e.g., with addition of glutathione, vitamin C, catalase, vitamin E, N-acetylcys teine). "Low oxidative stress," as used herein, refers to con ditions of no or minimal free radical damage to the cultured cells.
0064 Methods for the selection of the most appropriate culture medium, medium preparation, and cell culture tech niques are well known in the art and are described in a variety of sources, including Doyle et al., (eds.), 1995, Cell & Tissue Culture: Laboratory Procedures, John Wiley & Sons, Chich ester; and Ho and Wang (eds.) , 1991, Animal Cell Bioreac tors, Butterworth-Heinemann, Boston, which are incorpo rated herein by reference. 0065. In some embodiments of the invention, the UTC are passaged, or removed to a separate culture vessel containing fresh medium of the same or a different type as that used initially, where the population of cells can be mitotically expanded. The cells of the invention may be used at any point between passage 0 and senescence. The cells preferably are passaged between about 3 and about 25 times, more prefer ably are passaged about 4 to about 12 times, and preferably are passaged 10 or 11 times. Cloning and/or subcloning may be performed to confirm that a clonal population of cells has been isolated. Jun. 24, 2010 0066. In some aspects of the invention, the different cell types present in postpartum tissue are fractionated into Sub populations from which the UTC can be isolated. Fraction ation or selection may be accomplished using standard tech niques for cell separation including, but not limited to, enzymatic treatment to dissociate postpartum tissue into its component cells, followed by cloning and selection of spe cific cell types, including, but not limited to: Selection based on morphological and/or biochemical markers; selective growth of desired cells (positive selection); selective destruc tion of unwanted cells (negative selection); separation based upon differential cell agglutinability in the mixed population as, for example, with soybean agglutinin; freeze-thaw proce dures; differential adherence properties of the cells in the mixed population; filtration; conventional and Zonal centrifu gation; centrifugal elutriation (counter-streaming centrifuga tion); unit gravity separation; countercurrent distribution; electrophoresis; and fluorescence activated cell sorting (FACS). 0067. The culture medium is changed as necessary. For example, by carefully aspirating the medium from the dish with a pipette, and replenishing with fresh medium. Incuba tion is continued until a sufficient number or density of cells accumulate in the dish. Thereafter, any original explanted tissue sections that exist may be removed and the remaining cells separated from the dish by trypsinization using standard techniques or by using a cell Scraper. After trypsinization, the cells are collected, removed to fresh medium and incubated as above. In some embodiments, the medium is changed at least once at approximately 24 hours post-trypsinization to remove any floating cells. The cells remaining in culture are consid ered to be UTC.
0068. The UTC may be cryopreserved. Accordingly, in a preferred embodiment described in greater detail below, the UTC for autologous transfer (for either the mother or child) may be derived from appropriate postpartum tissues follow ing the birth of a child, then cryopreserved so as to be avail able in the event they are later needed for transplantation. 0069. The UTC may be characterized, for example, by growth characteristics (e.g., population doubling capability, doubling time, passages to senescence), karyotype analysis (e.g., normal karyotype; maternal or neonatal lineage), flow cytometry (e.g., FACS analysis), immunohistochemistry and/ or immunocytochemistry (e.g., for detection of epitopes), gene expression profiling (e.g., gene chip arrays; polymerase chain reaction (for example, reverse transcriptase PCR, real time PCR, and conventional PCR)), protein arrays, protein secretion (e.g., by plasma clotting assay or analysis of PDC conditioned medium, for example, by Enzyme LinkedImmu noSorbent Assay (ELISA)), mixed lymphocyte reaction (e.g., as measure of stimulation of PBMCs), and/or other methods known in the art.
(0070) Examples of UTC derived from umbilicus tissue were deposited with the AmericanType Culture Collection on Jun. 10, 2004, and assigned ATCC Accession Numbers as follows: (1) strain designation UMB 022803 (P7) was assigned Accession No. PTA-6067; and (2) strain designation UMB 022803 (P17) was assigned Accession No. PTA-6068. 0071. In various embodiments, the UTC possess one or more of the following growth features: (1) they require L-va line for growth in culture; (2) they are capable of growth in atmospheres containing oxygen from about 5% to about 20%: (3) they have the potential for at least about 40 doublings in culture before reaching senescence; and (4) they attach and expand on tissue culture vessels that are uncoated, or that are coated with gelatin, laminin, collagen, polyornithine, Vit ronectin or fibronectin.
0072. In certain embodiments the UTC possesses a normal karyotype, which is maintained as the cells are passaged. Methods for karyotyping are available and known to those of skill in the art.
0073. In other embodiments, the UTC may be character ized by production of certain proteins, including: (1) produc tion of at least one of tissue factor, vimentin, and alpha Smooth muscle actin; and (2) production of at least one of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A.B.C cell surface markers, as detected by flow cytometry. In other embodiments, the UTC may be charac terized by lack of production of at least one of CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA G, and HLA-DR, DP. DQ cell surface markers, as detected by flow cytometry. Particularly preferred are cells that produce at least two of tissue factor, vimentin; and alpha-Smooth muscle actin. More preferred are those cells producing all three of the proteins: tissue factor; Vimentin; and alpha Smooth muscle actin. 0074. In other embodiments, the UTC may be character ized by gene expression, which relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, is increased for a gene encoding at least one of interleukin 8; reticulon 1; chemokine (C X-C motif) ligand 1 (melonoma growth stimulating activity, alpha); chemokine (C X-C motif) ligand 6 (granulocyte chemot actic protein2); chemokine (C X-C motif) ligand 3; tumor necrosis factor, alpha-induced protein 3; C-type lectin Super family member 2: Wilms tumor 1; aldehyde dehydrogenase 1 family member A2; renin; oxidized low density lipoprotein receptor 1; Homo sapiens clone IMAGE:4179671; protein kinase C Zeta; hypothetical protein DKFZp564F013; down regulated in ovarian cancer 1; and Homo sapiens gene from clone DKFZp547k1113. 0075. In yet other embodiments, the UTC may be charac terized by gene expression, which relative to a humancell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, is reduced for a gene encoding at least one of short stature homeobox 2: heat shock 27 kDa protein 2: chemokine (C X-C motif) ligand 12 (stromal cell-derived factor 1); elastin (supravalvular aortic stenosis, Williams Beuren syndrome); Homo sapiens mRNA, cDNA DKFZp586M2022 (from clone DKFZp586M2022); mesen chyme homeobox 2 (growth arrest-specific homeobox); sine oculis homeobox homolog 1 (Drosophila); crystallin, alpha B; disheveled associated activator of morphogenesis 2: DKFZP586B2420 protein; similar to neuralin 1; tetranectin (plasminogen binding protein); Src homology three (SH3) and cysteine rich domain; cholesterol 25-hydroxylase; runt related transcription factor 3; interleukin 11 receptor, alpha; procollagen C-endopeptidase enhancer; frizzled homolog 7 (Drosophila); hypothetical gene BC008967; collagen, type VIII, alpha 1; tenascin C (hexabrachion); iroquois homeobox protein 5; hephaestin; integrin, beta 8: Synaptic vesicle gly coprotein 2; neuroblastoma, Suppression of tumorigenicity 1, insulin-like growth factor binding protein 2, 36 kDa; Homo sapiens cDNA FLJ12280 fis, clone MAMMA1001744: cytokine receptor-like factor 1; potassium intermediate/small conductance calcium-activated channel, Subfamily N. mem ber 4; integrin, beta 7; transcriptional co-activator with PDZ binding motif (TAZ); sine oculis homeobox homolog 2 Jun. 24, 2010 (Drosophila); KIAA1034 protein; vesicle-associated mem brane protein 5 (myobrevin); EGF-containing fibulin-like extracellular matrix protein 1; early growth response3; distal less homeo box. 5; hypothetical protein F1120373; aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II); biglycan; transcriptional co-activa tor with PDZ-binding motif (TAZ); fibronectin 1; proen kephalin; integrin, beta-like 1 (with EGF-like repeat domains); Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1968422; EphA3; KIAA0367 protein: natriuretic peptide receptor C/guanylate cyclase C (atrionatri uretic peptide receptor C): hypothetical protein F1114054; Homo sapiens mRNA, cDNA DKFZp564B222 (from clone DKFZp564B222); BCL2/adenovirus E1B 19 kDa interacting protein 3-like: AE binding protein 1; and cytochrome c oxi dase subunit VIIa polypeptide 1 (muscle). 0076. In other embodiments, the UTC may be character ized by secretion of at least one of MCP-1, IL-6: IL-8; GCP-2; HGF; KGF; FGF; HB-EGF; BDNF; TPO; MIP1a; RANTES; and TIMP1. In some embodiments, the UTC may be characterized by lack of secretion of at least one of TGF beta2: ANG2: PDGFbb; MIP1b: 1309: MDC; and VEGF, as detected by ELISA. (0077. In some preferred embodiments, the UTC is derived from umbilical cord tissue substantially free of blood, are capable of self-renewal and expansion in culture, require L-valine for growth, can grow in at least about 5% oxygen, and comprise at least one of the following characteristics: (1) the potential for at least about 40 doublings in culture; (2) the ability to attach and expand on an uncoated tissue culture vessel or one coated with gelatin, laminin, collagen, polyor nithine, vitronectin, or fibronectin; (3) production of vimentin and alpha-smooth muscle actin; (4) production of CD10. CD13, CD44, CD73, and CD90; and (5) expression of a gene, which relative to a human cell that is a fibroblast, a mesen chymal stem cell, or an iliac crest bone marrow cell, is increased for a gene encoding interleukin 8 and reticulon 1. In some embodiments, such UTC does not produce CD45 and CD 117. 0078. The UTC described above can be used in methods for treating a patient having peripheral vascular disease, can be used in pharmaceutical compositions for treating periph eral vascular disease, for example, wherein Such composi tions comprise the cells having these characteristics and a pharmaceutically acceptable carrier, and can be used in kits for making, using, and practicing Such methods and pharma ceutical compositions as described and exemplified herein. In addition, the UTC as described above can be used to generate conditioned cell culture media or to make preparations such as cell extracts and subcellular fractions that can be used for making, using, and practicing Such methods and pharmaceu tical compositions as described and exemplified herein. 0079. In preferred embodiments, the cell comprises two or more of the above-listed growth, protein/surface marker pro duction, gene expression or Substance-secretion characteris tics. More preferred is a cell comprising, three, four, five or more of the characteristics. Still more preferred are UTC comprising six, seven, eight or more of the characteristics. Still more preferred presently is a cell comprising all of above characteristics.
0080 Among cells that are presently preferred for use with the invention in several of its aspects are UTC having the characteristics described above, and more particularly, those wherein the cells have normal karyotypes and maintain nor mal karyotypes with passaging, and further wherein the cells express each of the markers CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, and HLA-A.B,C, and wherein the cells produce the immunologically-detectable proteins which cor respond to the listed markers. Still more preferred are those cells which, in addition to the foregoing, do not produce proteins corresponding to any of the markers CD31, CD34, CD45, CD117, CD141, or HLA-DR.DPDQ, as detected by flow cytometry. 0081 Certain cells having the potential to differentiate along lines leading to various phenotypes are unstable and thus can spontaneously differentiate. Presently preferred for use with the invention are cells that do not spontaneously differentiate, for example, along myoblast, skeletal muscle, vascular Smooth muscle, pericyte, hemangiogenic, angio genic, vasculogenic, or vascular endothelial lines. Preferred cells, when grown in growth medium, are Substantially stable with respect to the cell markers produced on their surface, and with respect to the expression pattern of various genes, for example, as determined using a medical diagnostic test sold under the trade name GENECHIP (Affymetrix, Inc., Santa Clara, Calif.). The cells remain substantially constant, for example, in their surface marker characteristics over passag ing and through multiple population doublings. 0082 Another aspect of the invention features the use of populations of a UTC described above. In some embodi ments, the cell population may be heterogeneous. A hetero geneous cell population of the invention may comprise at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% UTC of the invention. The heterogeneous cell populations of the invention may further comprise stem cells or other progenitor cells, such as myoblasts or other muscle progenitor cells, hemangioblasts, or blood vessel precursor cells; or it may further comprise fully differentiated skeletal muscle cells, Smooth muscle cells, pericytes, or blood vessel endothelial cells. In some embodiments, the population is Substantially homogeneous, i.e., comprises Substantially only the UTC (preferably at least about 96%, 97%, 98%, 99% or more UTC). The homogeneous cell population of the inven tion may comprise umbilicus-derived cells. Homogeneous populations of umbilicus-derived cells are preferably free of cells of maternal lineage. Homogeneity of a cell population may be achieved by any method known in the art, for example, by cell sorting (e.g., flow cytometry) or by clonal expansion in accordance with known methods. Thus, pre ferred homogeneous UTC populations may comprise a clonal cell line of postpartum-derived cells. Such populations are particularly useful when a cell clone with highly desirable functionality has been isolated. 0083. Also provided herein is the use of populations of cells incubated in the presence of one or more factors, or under conditions, that stimulate stem cell differentiation along a vascular Smooth muscle, Vascular endothelial, or peri cyte pathway. Such factors are known in the art and the skilled artisan will appreciate that determination of Suitable condi tions for differentiation can be accomplished with routine experimentation. Optimization of Such conditions can be accomplished by statistical experimental design and analysis, for example, response Surface methodology allows simulta neous optimization of multiple variables in a biological cul ture. Presently preferred factors include, but are not limited to, growth or trophic factors, chemokines, cytokines, cellular products, demethylating agents, and other stimuli which are now known or later determined to stimulate differentiation, Jun. 24, 2010 for example, of stem cells along angiogenic, hemangiogenic, vasculogenic, skeletal muscle, vascular Smooth muscle, peri cyte, or vascular endothelial pathways or lineages. I0084. The UTC may also be genetically modified to pro duce therapeutically useful gene products, to produce angio genic agents to facilitate or Support additional blood vessel formation or growth, or to produce factors to recruit endot helial progenitor cells to the area of lung damage. Endothelial progenitor cells facilitate vasculogenesis and blood flow, par ticularly following an ischemic event. (Urbich C and Dim meler S, Circ. Res., 2004: 95:343-53) . Factors that play a role in endothelial cell recruitment include, but are not limited to, VEGF, stromal derived factor-1 (SDF-1), erythropoietin (EPO), G-CSF, statins, strogen, PPAR-y, CXCR4, FGF, and HGF. Genetic modification may be accomplished using any of a variety of vectors including, but not limited to, integrating viral vectors, e.g., retrovirus vector or adeno-associated viral vectors; non-integrating replicating vectors, e.g., papilloma virus vectors, SV40 vectors, adenoviral vectors; or replica tion-defective viral vectors. Other methods of introducing DNA into cells include the use of liposomes, electroporation, a particle gun, or by direct DNA injection. I0085 Hosts cells are preferably transformed or trans fected with DNA controlled by, or in operative association with, one or more appropriate expression control elements Such as promoter or enhancer sequences, transcription termi nators, polyadenylation sites, among others, and a selectable marker. Any promoter may be used to drive the expression of the inserted gene. For example, viral promoters include, but are not limited to, the CMV promoter/enhancer, SV 40, pap illomavirus, Epstein-Barr virus or elastin gene promoter. In Some embodiments, the control elements used to control expression of the gene of interest can allow for the regulated expression of the gene so that the product is synthesized only when needed in vivo. If transient expression is desired, con stitutive promoters are preferably used in a non-integrating and/or replication-defective vector. Alternatively, inducible promoters could be used to drive the expression of the inserted gene when necessary. Inducible promoters include, but are not limited to, those associated with metallothionein and heat shock proteins. I0086 Following the introduction of the foreign DNA, engineered cells may be allowed to grow in enriched media and then switched to selective media. The selectable marker in the foreign DNA confers resistance to the selection and allows cells to stably integrate the foreign DNA as, for example, on a plasmid, into their chromosomes and grow to form foci which, in turn, can be cloned and expanded into cell lines. This method can be advantageously used to engineer cell lines that express the gene product. I0087. The cells of the invention may be genetically engi neered to "knockout' or "knock down" expression of factors that promote inflammation or rejection at the implant site. Negative modulatory techniques for the reduction of target gene expression levels or target gene product activity levels are discussed below. "Negative modulation, as used herein, refers to a reduction in the level and/or activity of target gene product relative to the level and/or activity of the target gene product in the absence of the modulatory treatment. The expression of a gene native to a skeletal muscle cell, vascular Smooth muscle cell, pericyte, vascular endothelial cell, or progenitor cells thereof can be reduced or knocked out using a number of techniques including, for example, inhibition of expression by inactivating the gene using the homologous recombination technique. Typically, an exon encoding an important region of the protein (or an exon 5' to that region) is interrupted by a positive selectable marker, e.g., neo, prevent ing the production of normal mRNA from the target gene and resulting in inactivation of the gene. A gene may also be inactivated by creating a deletion in part of a gene, or by deleting the entire gene. By using a construct with two regions of homology to the target gene that are far apart in the genome, the sequences intervening the two regions can be deleted. (Mombaerts et al., Proc. Nat. Acad. Sci. U.S. A., 1991; 88:3084-87) . Antisense, DNAZymes, ribozymes, small interfering RNA (siRNA) and other such molecules that inhibit expression of the target gene can also be used to reduce the level of target gene activity. For example, antisense RNA molecules that inhibit the expression of major histocompat ibility gene complexes (HLA) have been shown to be most versatile with respect to immune responses. Still further, triple helix molecules can be utilized in reducing the level of target gene activity. 0088. In other aspects, the invention utilizes cell lysates and cell soluble fractions prepared from a UTC, or heteroge neous or homogeneous cell populations comprising a UTC, as well as a UTC or populations thereofthat have been geneti cally modified or that have been stimulated to differentiate along a skeletal muscle, vascular Smooth muscle, pericyte, or vascular endothelium pathway. Such lysates and fractions thereof have many utilities. Use of the UTC lysate soluble fraction (i.e., substantially free of membranes) in vivo, for example, allows the beneficial intracellular milieu to be used allogeneically in a patient without introducing an appreciable amount of the cell Surface proteins most likely to trigger rejection, or other adverse immunological responses. Meth ods of lysing cells are well-known in the art and include various means of mechanical disruption, enzymatic disrup tion, or chemical disruption, or combinations thereof. Such cell lysates may be prepared from cells directly in their growth medium, and thus contain secreted growth factors and the like, or they may be prepared from cells washed free of medium in, for example, PBS or other solution. Washed cells may be resuspended at concentrations greater than the origi nal population density if preferred. 0089. In one embodiment, whole cell lysates are prepared, e.g., by disrupting cells without Subsequent separation of cell fractions. In another embodiment, a cell membrane fraction is separated from a soluble fraction of the cells by routine meth ods known in the art, e.g., centrifugation, filtration, or similar methods.
0090 Cell lysates or cell soluble fractions prepared from populations of postpartum-derived cells may be used as is, further concentrated by, for example, ultrafiltration or lyo philization, or even dried, partially purified, combined with pharmaceutically-acceptable carriers or diluents as are known in the art, or combined with other compounds such as biologicals, for example, pharmaceutically useful protein compositions. Cell lysates or fractions thereofmay be used in vitro or in vivo, alone or, for example, with autologous or Syngeneic live cells. The lysates, if introduced in Vivo, may be introduced locally at a site of treatment, or remotely to pro vide, for example, needed cellular growth factors to a patient. 0091 Inafurther embodiment, the UTC can be cultured in vitro to produce biological products in high yield. AUTC that either naturally produces a particular biological product of interest (e.g., a trophic factor), or that has been genetically engineered to produce a biological product, can be clonally expanded using the culture techniques described herein. Alternatively, cells may be expanded in a medium that induces differentiation to a skeletal muscle, vascular Smooth muscle, pericyte, or vascular endothelial lineage. In each case, biological products produced by the cell and secreted into the medium can be readily isolated from the conditioned medium using standard separation techniques, e.g., Such as differential protein precipitation, ion-exchange chromatogra phy, gel filtration chromatography, electrophoresis, and HPLC, to name a few. A "bioreactor" may be used to take advantage of the flow method for feeding, for example, a three-dimensional culture in vitro. Essentially, as fresh media is passed through the three-dimensional culture, the biologi cal product is washed out of the culture and may then be isolated from the outflow, as above.
0092 Alternatively, a biological product of interest may remain within the cell and, thus, its collection may require that the cells be lysed, as described above. The biological product may then be purified using any one or more of the above-listed techniques. 0093. In other embodiments, the invention utilizes condi tioned medium from cultured UTC foruse invitro and in vivo as described below. Use of the UTC conditioned medium allows the beneficial trophic factors secreted by the UTC to be used allogeneically in a patient without introducing intact cells that could trigger rejection, or other adverse immuno logical responses. Conditioned medium is prepared by cul turing cells in a culture medium, then removing the cells from the medium.
0094 Conditioned medium prepared from populations of umbilical cord-derived cells may be used as is, further con centrated, for example, by ultrafiltration or lyophilization, or even dried, partially purified, combined with pharmaceuti cally acceptable carriers or diluents as are known in the art, or combined with other compounds Such as biologicals, for example, pharmaceutically useful protein compositions. Conditioned medium may be used in vitro or in vivo, alone or combined with autologous or Syngeneic live cells, for example. The conditioned medium, if introduced in vivo, may be introduced locally at a site of treatment, or remotely to provide needed cellular growth or trophic factors to a patient. 0.095. In another embodiment, an extracellular matrix (ECM) produced by culturing the UTC on liquid, solid or semi-solid Substrates is prepared, collected and utilized as an alternative to implanting live cells into a Subject in need of tissue repair or replacement. The UTC is cultured in vitro, on a three dimensional framework as described elsewhere herein, under conditions such that a desired amount of ECM is secreted onto the framework. The cells comprising the new tissue are removed, and the ECM processed for further use, for example, as an injectable preparation. To accomplish this, cells on the framework are killed and any cellular debris is removed from the framework. This process may be carried out in a number of different ways. For example, the living tissue can be flash-frozen in liquid nitrogen without a cryo preservative, or the tissue can be immersed insterile distilled water so that the cells burst in response to osmotic pressure. 0096. Once the cells have been killed, the cellular mem branes may be disrupted and cellular debris removed by treat ment with a mild detergent rinse, such as EDTA, CHAPS or a Zwitterionic detergent. Alternatively, the tissue can be enzy matically digested and/or extracted with reagents that break down cellular membranes and allow removal of cell contents. 0097. The collection of the ECM can be accomplished in a variety of ways, depending at least in part on whether the new tissue has been formed on a three-dimensional framework that is biodegradable or non-biodegradable, as in the case of metals. For example, if the framework is non-biodegradable, the ECM can be removed by subjecting the framework to Sonication, high pressure water jets, mechanical scraping, or mild treatment with detergents or enzymes, or any combina tion of the above.
0098. If the framework is biodegradable, the ECM can be collected, for example, by allowing the framework to degrade or dissolve in solution. Alternatively, if the biodegradable framework is composed of a material that can itself be injected along with the ECM, the framework and the ECM can be processed in toto for Subsequent injection. Alterna tively, the ECM can be removed from the biodegradable framework by any of the methods described above for collec tion of ECM from a non-biodegradable framework. All col lection processes are preferably designed so as not to dena ture the ECM. 0099. After it has been collected, the ECM may be pro cessed further. For example, the ECM can be homogenized to fine particles using techniques well known in the art such as by Sonication, so that it can pass through a Surgical needle. The components of the ECM can also be crosslinked, if desired, by gamma irradiation. Preferably, the ECM can be irradiated between 0.25 to 2 mega rads to sterilize and crosslink the ECM. Chemical crosslinking using agents that are toxic, such as glutaraldehyde, is possible but not generally preferred. 0100. The amounts and/or ratios of proteins, such as the various types of collagen present in the ECM, may be adjusted by mixing the ECM produced by the cells of the invention with ECM of one or more other cell types. In addition, biologically active Substances such as proteins, growth factors and/or drugs, can be incorporated into the ECM. Exemplary biologically active substances include tis Sue growth factors, such as TGF-beta, and the like, which promote healing and tissue repair at the site of the injection. Such additional agents may be utilized in any of the embodi ments described herein above, e.g., with whole cell lysates, soluble cell fractions, or further purified components and products produced by the UTC. 0101. In another aspect, the invention provides pharma ceutical compositions that utilize the UTC, UTC populations, components and products of the UTC in various methods for the treatment of injury or damage caused by a peripheral ischemic episode. Certain embodiments encompass pharma ceutical compositions comprising live cells (UTC alone or admixed with other cell types). Other embodiments encom pass pharmaceutical compositions comprising UTC cellular Jun. 24, 2010 components (e.g., cell lysates, soluble cell fractions, condi tioned medium, ECM, or components of any of the foregoing) or products (e.g., trophic and other biological factors pro duced naturally by the UTC or through genetic modification, conditioned medium from UTC culture). The UTC compo nents and products that can be used in the present invention are described in U.S. Patent Publication Nos. 2005/0032209, 2005/0058631 and 2005/0054098, and are incorporated herein by reference. In either case, the pharmaceutical com position may further comprise other active agents, such as anti-inflammatory agents, anti-apoptotic agents, antioxi dants, growth factors, myotrophic factors or myoregenerative or myoprotective drugs as known in the art. 0102 Pharmaceutical compositions comprising UTC live cells are typically formulated as liquids, semisolids (e.g., gels) or Solids (e.g., matrices, Scaffolds and the like, as appro priate for vascular or lung tissue engineering). Liquid com positions are formulated for administration by any acceptable route known in the art to achieve delivery of live cells to the target vascular or lung tissues. Typically, these include injec tion or infusion, either in a diffuse fashion, or targeted to the site of lung injury, damage, or distress, by a route of admin istration including, but not limited to, intramuscular, intrave nous, or intra-arterial delivery via Syringes with needles and/ or catheters with or without pump devices. 0103 Pharmaceutical compositions comprising live cells in a semi-solid or solid carrier are typically formulated for Surgical implantation at the site of lung injury, damage, or distress. It will be appreciated that liquid compositions also may be administered by Surgical procedures. In particular embodiments, semi-solid or Solid pharmaceutical composi tions may comprise semi-permeable gels, lattices, cellular scaffolds and the like, which may be non-biodegradable or biodegradable. For example, in certain embodiments, it may be desirable or appropriate to sequester the exogenous cells from their Surroundings, yet enable the cells to secrete and deliver biological molecules (e.g. myotrophic factors, angiotrophic factors, or endothelial progenitor cell recruit ment factors) to Surrounding lung tissue or vascular cells. In these embodiments, cells may be formulated as autonomous implants comprising a living UTC or cell population com prising a UTC Surrounded by a non-degradable, selectively permeable barrier that physically separates the transplanted cells from host tissue. Such implants are sometimes referred to as "immunoprotective." as they have the capacity to prevent immune cells and macromolecules from killing the trans planted cells in the absence of pharmacologically induced immunosuppression. 0104. In other embodiments, different varieties of degrad able gels and networks are utilized for the pharmaceutical compositions of the invention. For example, degradable materials particularly Suitable for Sustained release formula tions include biocompatible polymers, such as poly(lactic acid), poly (lactic acid-co-glycolic acid), methylcellulose, hyaluronic acid, collagen, and the like. 0105. In other embodiments, it may be desirable or appro priate to deliver the cells on or in a biodegradable, preferably bioresorbable or bioabsorbable, scaffold or matrix. These, typically three-dimensional, biomaterials contain the living cells attached to the scaffold, dispersed within the scaffold, or incorporated in an extracellular matrix entrapped in the scaf fold. Once implanted into the target region of the body, these implants become integrated with the host tissue, wherein the transplanted cells gradually become established. (See, e.g., Tresco, PA, et al., Adv. Drug Delivery Rev., 2000; 42:3-27 ; see also, Hutmacher, D. W. J. Biomater. Sci. Polymer Edn., 2001: 12:107-174) . 0106 The biocompatible matrix may be comprised of natural, modified natural or synthetic biodegradable poly mers, including homopolymers, copolymers and block poly mers, as well as combinations thereof. It is noted that a poly mer is generally named based on the monomer from which it is synthesized. 0107 Examples of suitable biodegradable polymers or polymer classes include fibrin, collagen, elastin, gelatin, Vit ronectin, fibronectin, laminin, thrombin, poly(aminoacid), oxidized cellulose, tropoelastin, silk, ribonucleic acids, deox yribonucleic acids, proteins, polynucleotides, reconstituted basement membrane matrices, starches, dextrans, alginates, hyaluron, chitin, chitosan, agarose, polysaccharides, hyalu ronic acid, poly(lactic acid), poly(glycolic acid), polyethyl ene glycol, decellularized tissue, self-assembling peptides, polypeptides, glycosaminoglycans, their derivatives and mix tures thereof. For both glycolic acid and lactic acid, an inter mediate cyclic dimer is typically prepared and purified prior to polymerization. These intermediate dimers are called gly collide and lactide, respectively. Other useful biodegradable polymers or polymer classes include, without limitation, ali phatic polyesters, poly(alkylene oxalates), tyrosine derived polycarbonates, polyiminocarbonates, polyorthoesters, poly oxaesters, polyamidoesters, polyoxaesters containing amine groups, poly(propylene fumarate), polydioxanones, polycar bonates, polyoxalates, poly(alpha-hydoxyacids), poly(es ters), polyurethane, poly(ester urethane), poly(ether ure thane), polyanhydrides, polyacetates, polycaprolactones, poly(orthoesters), polyamino acids, polyamides and blends and copolymers thereof. Additional useful biodegradable polymers include, without limitation, Stereopolymers of L and D-lactic acid, copolymers of bis(para-carboxyphenoxy) propane and sebacic acid, sebacic acid copolymers, copoly mers of caprolactone, poly(lactic acid)/poly(glycolic acid)/ polyethyleneglycol copolymers, copolymers of polyurethane and poly(lactic acid), copolymers of alpha-amino acids, copolymers of alpha-amino acids and caproic acid, copoly mers of alpha-benzyl glutamate and polyethylene glycol, copolymers of Succinate and poly(glycols), polyphosp haZene, poly(hydroxyalkanoates) and mixtures thereof. Binary and ternary systems also are contemplated. 0108. In general, a suitable biodegradable polymer for use as the matrix is desirably configured so that it: (1) has mechanical properties that are suitable for the intended appli cation; (2) remains sufficiently intact until tissue has in-grown and healed; (3) does not invoke an inflammatory or toxic response; (4) is metabolized in the body after fulfilling its purpose; (5) is easily processed into the desired final prod uct to be formed; (6) demonstrates acceptable shelf-life; and (7) is easily sterilized. 0109. In one aspect of the invention, the biocompatible polymer used to form the matrix is in the form of a hydrogel. In general, hydrogels are cross-linked polymeric materials that can absorb more than 20% of their weight in water while maintaining a distinct three-dimensional structure. This defi nition includes dry cross-linked polymers that will swell in aqueous environments, as well as water-swollen materials. A host of hydrophilic polymers can be cross-linked to produce hydrogels, whether the polymer is of biological origin, semi synthetic, or wholly synthetic. The hydrogel may be pro duced from a synthetic polymeric material. Such synthetic polymers can be tailored to a range of properties and predict able lot-to-lot uniformity, and represent a reliable source of material that generally is free from concerns of immunoge nicity. The matrices may include hydrogels formed from self assembling peptides. Such as those discussed in U.S. Pat. Nos. 5,670,483 and 5,955,343, U.S. Patent Application No. 2002/ 0160471 , and PCT Application No. WO 02/062969. 0110 Properties that make hydrogels valuable in drug delivery applications include the equilibrium Swelling degree, sorption kinetics, solute permeability, and their in Vivo performance characteristics. Permeability to compounds depends in part upon the Swelling degree or water content and the rate of biodegradation. Since the mechanical strength of a gel declines in direct proportion to the Swelling degree, it is also well within the contemplation of the present invention that the hydrogel can be attached to a substrate so that the composite system enhances mechanical strength. In some embodiments, the hydrogel can be impregnated within a porous Substrate, so as to gain the mechanical strength of the substrate, along with the useful delivery properties of the hydrogel. 0111 Non-limiting examples of scaffold or matrix (some times referred to collectively as "framework') that may be used in the present invention include textile structures such as weaves, knits, braids, meshes, non-wovens, and warpedknits: porous foams, semi-porous foams, perforated films or sheets, microparticles, beads, and spheres and composite structures being a combination of the above structures. Non-woven mats may, for example, be formed using fibers comprised of a synthetic absorbable copolymer of glycolic and lactic acids (PGA/PLA), sold under the tradename VICRYL sutures (Ethicon, Inc., Somerville, N.J.). Foams, composed of, for example, poly(epsilon-caprolactone)/poly(glycolic acid) (PCL/PGA) copolymer, formed by processes such as freeze drying, or lyophilization, as discussed in U.S. Pat. No. 6,355, 699, also may be utilized. Hydrogels such as self-assembling peptides (e.g., RAD 16) may also be used. In situ-forming degradable networks are also suitable for use in the invention. (See, e.g., Anseth, K S et al., J. Controlled Release, 2002: 78:199-209; Wang, D. et al., Biomaterials, 2003; 24:3969 3980 ; U.S. Patent Publication 2002/0022676). These in situ forming materials are formulated as fluids suitable for injec tion, then may be induced to form a hydrogel by a variety of means such as change in temperature, pH, and exposure to light in situ or in vivo. 0.112. In another embodiment, the framework is a felt, which can be composed of a multifilament yarn made from a bioabsorbable material, e.g., PGA, PLA, PCL copolymers or blends, or hyaluronic acid. The yarn is made into a felt using standard textile processing techniques consisting of crimp ing, cutting, carding and needling. In another embodiment, cells are seeded onto foam scaffolds that may be composite Structures. 0113. In many of the above mentioned embodiments, the framework may be molded into a useful shape. Such as that of a blood vessel. Furthermore, it will be appreciated that UTC may be cultured on pre-formed, non-degradable Surgical or implantable devices, e.g., in a manner corresponding to that used for preparing fibroblast-containing GDC endovascular coils, for instance. (Marx, W F, et al., Am. J. Neuroradiol., 2001:22:323-333) . 0114. The matrix, scaffold or device may be treated prior to the inoculation of cells in order to enhance cell attachment.
For example, prior to inoculation, nylon matrices can be treated with 0.1 molar acetic acid and incubated in polylysine, PBS, and/or collagen to coat the nylon. Polystyrene can be similarly treated using Sulfuric acid. The external Surfaces of a framework may also be modified to improve the attachment or growth of cells and differentiation of tissue, such as by plasma coating the framework or addition of one or more proteins (e.g., collagens, elastic fibers, reticular fibers), gly coproteins, glycosaminoglycans (e.g., heparin Sulfate, chon droitin-4-Sulfate, chondroitin-6-sulfate, dermatan Sulfate, keratin Sulfate), genetic materials such as cytokines and growth factors, a cellular matrix, and/or other materials, including, but not limited to, gelatin, alginates, agar, agarose, and plant gums, among other factors affecting cell Survival and differentiation.
0115 UTC-containing frameworks are prepared accord ing to methods known in the art. For example, cells can be grown freely in a culture vessel to Sub-confluency or conflu ency, lifted from the culture and inoculated onto the frame work. Growth factors may be added to the culture medium prior to, during, or Subsequent to inoculation of the cells to trigger differentiation and tissue formation, if desired. Alter natively, the frameworks themselves may be modified so that the growth of cells thereon is enhanced, or so that the risk of rejection of the implant is reduced. Thus, one or more bio logically active compounds, including, but not limited to, anti-inflammatory compounds, immunosuppressants or growth factors, may be added to the framework for local release. 0116. A UTC, parts of a UTC, or cell populations com prising a UTC, or components of or products produced by a UTC, may be used in a variety of ways to support and facili tate the repair, regeneration, and improvement of lung cells and tissues, to improve blood flow, and to stimulate and/or Support angiogenesis, especially in lung disease patients. Such utilities encompass in vitro, ex vivo and in vivo meth ods. 0117. In one embodiment, as discussed above, the UTC can be cultured in vitro to produce biological products that are either naturally produced by the cells, or produced by the cells when induced to differentiate into lung tissue, or produced by the cells via genetic modification. For instance, TIMP1 TPO, KGF, HGF, FGF, HBEGF, BDNF, MIP1b, MCPJ, RANTES, 1309, TARC, MDC, and IL-8 were found to be secreted from umbilicus-derived cells grown in growth medium. (See Examples). In addition, factors for endothelial progenitor cell recruitment such as VEGF, SDF-1, EPO, G-CSF, statins, estrogen, PPAR-y, and CXCR4 may be produced by the UTC and may be secreted into the growth medium. Other trophic factors, as yet undetected or unexamined, of use in lung tissue or vascular repair and regeneration, are likely to be produced by the UTC and possibly secreted into the medium. 0118. In this regard, another embodiment of the invention features use of the UTC for production of conditioned medium, either from an undifferentiated UTC or from a UTC conditions in which the two cell types are in contact. This can be achieved, for example, by seeding the cells as a heteroge neous population of cells in culture medium or onto a Suitable culture substrate. Alternatively, the UTC can first be grown to confluence, and then will serve as a substrate for the second desired cell type in culture. In this latter embodiment, the cells may further be physically separated, e.g., by a membrane or similar device, such that the other cell type may be removed and used separately, following the co-culture period. Use of the UTC in co-culture to promote expansion and differentia tion of lung tissue or vascular cell types may find applicability in research and in clinical/therapeutic areas. For instance, UTC co-cultures may be utilized to facilitate growth and differentiation of lung tissue, for example, vascular Smooth muscle, pericytes, or vascular endothelial cells, in culture, for basic research purposes or for use in drug screening assays, for example. UTC co-cultures may also be utilized for ex vivo expansion of for example, Vascular Smooth muscle, pericyte, or vascular endothelium progenitors for later administration for therapeutic purposes. Lung tissue, for example, vascular Smooth muscle, pericyte, or vascular endothelium progenitor cells, may be harvested from an individual, expanded ex vivo in co-culture with UTC, then returned to that individual (au tologous transfer) or another individual (syngeneic or alloge neic transfer). In these embodiments, it will be appreciated that, following ex vivo expansion, the mixed population of cells comprising the UTC and lung tissue, for example, vas cular Smooth muscle, pericyte, or vascular endothelium pro genitors, could be administered to a patient in need of treat ment. Alternatively, in situations where autologous transfer is appropriate or desirable, the co-cultured cell populations may be physically separated in culture, enabling removal of the autologous lung tissue, for example vascular Smooth muscle, or vascular endothelium progenitors, for administration to the patient. UTC, and components and products thereof, have been shown to be effectively transplanted into the body, and to improve blood flow and reduce tissue necrosis in an accepted animal model. Those findings, along with the discoveries set forth in the present invention, support preferred embodiments of the invention, wherein the UTC is used in cell therapy for treating lung injury or damage by repairing or regenerating lung tissue and/or vascular tissue in a lung damaged patient, or by improving blood flow or stimulating and/or supporting angiogenesis in a lung damaged patient. In one embodiment, the UTC is transplanted into a target location in the body, especially at or proximal to the location of the lung damage, where the UTC can differentiate into one or more of lung tissue phenotypes, for example, vascular Smooth muscle, pericyte, or vascular endothelium phenotypes, the UTC can provide trophic Support for lung tissue, for example, Vascular Smooth muscle cell, pericyte, or vascular endothelial cell progenitors and/or lung tissue cells. In situ, the UTC can produce factors to recruit endothelial progenitor cells to the site of the lung injury, or the UTC can exerta beneficial effect in two or more of those fashions, among others. The UTC secretes trophic factors including, but not limited to GFGFm, 0122) The UTC can exert trophic effects in the body of the patient to which they are administered. For example, the UTC can exert trophic effects on lung tissue cells, for example, vascular Smooth muscle cells, vascular endothelial cells, peri cytes, or progenitor cells, thereof. In some preferred embodi ments, the trophic effect is the proliferation of such cells. The UTC can also induce migration of cells in the body of the patient to which they are administered. Such migration can facilitate the repair, regeneration, and treatment of lung dis ease, disorders, and/or injuries, such as COPD, ALI, ARDS, and pulmonary fibrosis. For example, a UTC administered at or near a site of lung damage can induce migration of cells to the site of lung damage in order to repair, regenerate, or otherwise treat the diseased tissue and its Surroundings. The UTC so administered can induce migration of lung tissue cells, for example, vascular Smooth muscle cells, vascular endothelial cells, pericytes, or progenitor cells, thereof. In preferred embodiments, the UTC induces migration of vas cular endothelial cells and/or vascular endothelium progeni tor cells to the site, or at least near to the site of the lung damage. In some embodiments, migration is induced or Sup ported by FGF and/or HGF, preferably FGF and HGF expressed by the UTC. Preparations made from the UTC, including cell lysates, Subcellular fractions, products, and the like, can also be used to treat lung disease, disorders and/or injuries. Such preparations can be formulated with pharma ceutically acceptable carriers such as those described and exemplified herein, and administered to patients in amounts effective to treat lung disease, disorders and/or injuries. In preferred embodiments, preparations made from the UTC comprise FGF and HGF. 0123 Specific embodiments of the invention are directed to the direct repair, regeneration or replacement of, or the Support of the repair, regeneration, or replacement of blood vessels for the treatment of lung injury or damage. 0.124. The UTC may be administered alone (e.g., as sub stantially homogeneous populations) or as admixtures with other cells. As described above, the UTC may be adminis tered as formulated in a pharmaceutical preparation with a matrix or scaffold, or with conventional pharmaceutically acceptable carriers. Where the UTC is administered with other cells, they may be administered simultaneously or sequentially with the other cells (either before or after the other cells (0.125. The UTC may be administered with other beneficial drugs or biological molecules, or other active agents, such as anti-inflammatory agents, anti-apoptotic agents, antioxi dants, growth factors, angiogenic factors, or myoregenerative or myoprotective drugs as known in the art. When the UTC is administered with other agents, they may be administered together in a single pharmaceutical composition, or in sepa rate pharmaceutical compositions, simultaneously or sequen tially with the other agents (either before or after administra tion of the other agents). The other agents may be a part of a treatment regimen that begins either before transplantation and continuing throughout the course of recovery, or may be initiated at the time of transplantation, or even after transplan tation, as a physician of skill in the art deems appropriate. 0.126 In one embodiment, the UTC is administered as undifferentiated cells, i.e., as cultured in growth medium. Alternatively, the UTC may be administered following expo sure in culture to conditions that stimulate differentiation toward a desired lung tissue phenotype, for example, vascular Smooth muscle, pericyte, or vascular endothelium pheno types.
I0127. The cells of the invention may be surgically implanted, injected, delivered (e.g., by way of a catheter, Syringe, shunt, stent, microcatheter, or pump), or otherwise administered directly or indirectly to the site of lung injury, damage, or distress. Routes of administration of the cells of the invention, or compositions thereof, include, but are not limited to, intravenous, intramuscular, Subcutaneous, intrana sal, intrathecal, intracisternal, or via Syringes with needles or catheters with or without pump devices. 0128. When cells are administered in semi-solid or solid devices, Surgical implantation into a precise location in the body is typically a suitable means of administration. Liquid or fluid pharmaceutical compositions, however, may be admin istered through the blood, or directly into affected lung tissue (e.g., throughout a diffusely affected area, such as would be the case for diffuse ALI or ARDS). The migration of the UTC can be guided by chemical signals, growth factors, or calpains. I0129. The umbilical cord tissue-derived cells, or compo sitions and/or matrices comprising the umbilical cord tissue derived cells, may be delivered to the site via a micro catheter, intracatheterization, or via a mini-pump. The vehicle excipi ent or carrier can be any of those known to be pharmaceuti cally acceptable for administration to a patient, particularly locally at the site at which cellular differentiation is to be induced. Examples include liquid media, for example, Dul beccos Modified Eagle's Medium (DMEM), sterile saline, sterile phosphate buffered saline, Leibovitz's medium (L15, Invitrogen, Carlsbad, Calif.), dextrose in sterile water, and any other physiologically acceptable liquid. 0.130. Other embodiments encompass methods of treating lung injury or damage by administering therapeutic compo sitions comprising a pharmaceutically acceptable carrier and UTC cellular components (e.g., cell lysates or components thereof) or products (e.g., trophic and other biological factors produced naturally by the UTC or through genetic modifica tion, conditioned medium from UTC culture), or UTC growth medium or products purified from growth medium. In pre ferred embodiments, the biological factors are FGF and HGF. These methods may further comprise administering other active agents, such as growth factors, angiogenic factors or myoregenerative or myoprotective drugs as known in the art. 0131 Dosage forms and regimes for administering the UTC or any of the other therapeutic or pharmaceutical com positions described herein are developed in accordance with good medical practice, taking into account the condition of the individual patient, e.g., nature and extent of the injury or damage from the lung damaging event, age, sex, body weight and general medical condition, and other factors known to medical practitioners. Thus, the effective amount of a phar maceutical composition to be administered to a patient is determined by these considerations as known in the art. 0132) The UTC has been shown not to stimulate alloge neic PBMCs in a mixed lymphocyte reaction. Accordingly, allogeneic, or even Xenogeneic, transplantation of UTC may be tolerated in Some instances. In some embodiments, the UTC itself provides an immunosuppressant effect, thereby preventing host rejection of the transplanted UTC. In such instances, pharmacological immunosuppression during cell therapy may not be necessary. 0133. However, in other instances it may be desirable or appropriate to pharmacologically immunosuppress a patient prior to initiating cell therapy. This may be accomplished through the use of systemic or local immunosuppressive agents, or it may be accomplished by delivering the cells in an encapsulated device, as described above. These and other means for reducing or eliminating an immune response to the transplanted cells are known in the art. As an alternative, the UTC may be genetically modified to reduce their immuno genicity, as mentioned above. 0134) Survival of the transplanted UTC in a living patient can be determined through the use of a variety of scanning techniques, e.g., computerized axial tomography (CAT or CT) scan, magnetic resonance imaging (MRI) or positron emission tomography (PET) scans. Determination of trans plant Survival can also be done post mortem by removing the lung tissue or vascular tissue, and examining it visually or through a microscope. Alternatively, cells can be treated with stains that are specific for lung tissue cells, for example, vascular Smooth muscle cells, pericytes, or vascular endothe lial cells. Transplanted cells can also be identified by prior incorporation of tracer dyes Such as rhodamine-or fluores cein-labeled microspheres, fast blue, ferric microparticles, bisbenzamide or genetically introduced reporter gene prod ucts, such as beta-galactosidase or beta-glucuronidase. 0135) In another aspect, the invention provides kits that utilize the UTC, UTC populations, components and products of the UTC in various methods for stimulating and/or sup porting angiogenesis, for improving blood flow, for regener ating, repairing, and improving lung tissue injured or dam aged by a lung damaging event, as described above. Where used for treatment of damage or injury caused by a lung disease, disorders and/or injuries, or other scheduled treat ment, the kits may include one or more cell populations, including at least the UTC and a pharmaceutically acceptable carrier (liquid, semi-solid or solid). The kits also optionally may include a means of administering the cells, for example by injection. The kits further may include instructions for use of the cells. Kits prepared for field hospital use, such as for military use, may include full-procedure Supplies including tissue scaffolds, Surgical Sutures, and the like, where the cells are to be used in conjunction with repair of acute injuries. Kits Jun. 24, 2010 for assays and in vitro methods as described herein may contain one or more of (1) a UTC or components or products of the UTC, (2) reagents for practicing the invitro method, (3) other cells or cell populations, as appropriate, and (4) instruc tions for conducting the in vitro method. 0.136 The following examples describe several aspects of embodiments of the invention in greater detail. These examples are intended to further illustrate aspects of the invention described herein. These examples should not be construed to limit the aspect so exemplified. were slowly administered to mice by intravenous tail vein injection using a lm, Syringe and a 26-gauge needle and animals were then exposed to either room air or 90% O. Exposure to 90% O. was accomplished by placing the ani mals into a BioSpherix chamber (BioSpherix, LTD, Lacona, N.Y.) that has been primed and equilibrated to 90% O, for 1 hr. Supportive care (heat support and NutriCal) was provided daily for these animals. Animal observations, mortality, Sur vival, and percent oxygen concentrations for each tank were recorded two times a day. On day four post treatment, animals were euthanized using 50 mg/mL Nembutal (pentobarbital). Each rat strain will be randomized by body weight into three groups (Table 2-1). SD rats will then be exposed whole-body to tobacco smoke (total particulate concentration 75-85 mg/m (3)) or filtered room air for 6 h/day for 15 days (3 days/wk). 0164. Dose Preparation 0.165. On day 15, Smoking treatment will be terminated and hUTC or PBS vehicle will be administered. Immediately prior to injection, hUTC will be thawed at 37°C. (water bath), washed two times in phosphate buffered saline (PBS) and resuspended in lmL of PBS. Cells will be counted using a hemocytometer. Cell viability will be determined by trypan blue dye exclusion. Cells will be reconstituted at the appro priate concentrations of 1e cells and 3e cells in 2 mL of PBS.
Cells will be slowly administered via tail vein injection over a two-minute interval.
0166 Two weeks after vehicle or hUTC injections, the animals will be sacrificed to harvest bronchoalveolar lavage fluid (BALF) (8 animals/treatment group) and lung tissue (8 animals/treatment group). (0167 BALF Preparation 0168 To prepare BALF, eight animals per treatment group will be euthanized and lungs will be lavaged once with 1.0mL sterile PBS (Invitrogen) and the tubes containing fresh BALF will be placed on wet ice. The BALF will be centrifuged at 1000 rpm for 5 min and the supernatant fluid will be removed and used for further analysis.
(0169 BALF Cytokine Analysis (0170 BALF cytokine/chemokine levels will be deter mined using a mouse 22-multiplex bead kit (Millipore) fol lowing the manufacturer's protocol and analyzed using the Jun. 24, 2010
BioRad Bioplex machine. The results will be graphed and analyzed using GraphPad Prism Software.
(0171 BALF Total Protein Analysis 0172 To determine the total protein in each sample, cell free BALF will be analyzed using a BCA Protein Assay (Pierce). Analysis will be completed using the Softmax 4.0 program and data will be graphed using Graph Pad Prism Software.
(0173 Histology 0.174 Lungs will be harvested from eight animals per treatment group. Half of each lung will be fixed with 10% formaldehyde neutral buffer solution for 24 hours, dehy drated in a graded ethanol series, embedded in paraffin, and sliced at 5 um. Paraffin sections will be stained with hema toxylin-eosin (HE) and Masson for histopathologic analysis. The remaining lung half will be Snap frozen and processed for MPO and human cell detection (see below).
(0175 Myeloperoxidase (MPO) Activity 0176 About 200 mg lung tissue from the right upper lobe will be homogenated in 20 mmol/L. kalium phosphate buffer (pH7.4) and ultra-centrifuged. The precipitation will be pre served at -70° C. with HTAB for MPO measurement. The MPO activity will then be determined.
(0177 RNA Isolation (0178 Total RNA will be isolated from all snap-frozen lung tissue by Asuragen, Inc., according to the company's standard operating procedures. The purity and quantity of total RNA samples will be determined by absorbance read ings at 260 and 280 nm using a NanoDrop ND-1000 UV spectrophotometer. RNA integrity will be evaluated using an Agilent Bioanalyzer. 0179 Human Cell Detection 0180 Human-specific assays for GAPDH mRNA (Hs99999905 ml GAPDH) will be used to estimate the number of hUTC within mouse lung tissue. Samples for quantitative RT-PCR (qRT-PCR) analysis using single-tube TaqMan(R) Assays (Applied Biosystems) will be processed by Asuragen, Inc., according to the company's standard operat ing procedures. Dilutions of total RNA will be reverse tran scribed using the Tag Man(R) High Capacity cDNA Synthesis Kit (Applied BioSystems) according to the manufacturer's instructions and in a total reaction volume of 20 microliters per dilution. 50 ng input cloNA will then be analyzed by PCR. All amplifications will be performed in triplicate on a vali dated ABI 7500 real-time thermocycler. Following incuba tion at 95°C. for 10 minutes, samples will be amplified in 40 cycles of 95°C. for 15 seconds, then 60° C. for 1 minute. will be obtained and randomly divided into four groups with sixteen rats in each group. Animals will be per fused intratracheally with 5 mg/kg. BLM. Immediately prior to injection, hUTC will be thawed at 37° C. (water bath), washed two times in phosphate buffered saline (PBS) and resuspended in 1 mL of PBS. Cells will be counted using a hemocytometer. Cell viability will be determined by trypan blue dye exclusion. Cells will be reconstituted at the appro priate concentrating in 2 mL of PBS. Cells will be slowly administered via tail vein injection over a two-minute inter val. The study design is summarized in Table 3-1 below. 0185. In the hUTC treatment groups, 0.1-x10, 1x10° or 3x10 hUTC will be injected into the tail vein twelve hours after BLM perfusion. PBS vehicle alone will be administered in a similar fashion as in the hUTC treatment groups. Two weeks after vehicle or hUTC injections, the animals will be sacrificed to harvestbronchoalveolar lavage fluid (BALF) (8 animals/treatment group) and lung tissue (8 animals/treat ment group). 0186 BALF Preparation 0187 To prepare BALF, eight animals per treatment group will be euthanized and lungs will be lavaged once with 1.0mL sterile PBS (Invitrogen) and the tubes containing fresh BALF will be placed on wet ice. The BALF will be centrifuged at 1000 rpm for 5 min and the supernatant fluid will be removed and used for further analysis. 0188 BALF Cytokine Analysis (0189 BALF cytokine/chemokine levels will be deter mined using a mouse 22-multiplex bead kit (Millipore) fol lowing the manufacturer's protocol and analyzed using the BioRad Bioplex machine. The results will be graphed and analyzed using GraphPad Prism Software. (0190. BALF Total Protein Analysis 0191 To determine the total protein in each sample, cell free BALF will be analyzed using a BCA Protein Assay (Pierce). Analysis will be completed using the Softmax 4.0 program and data will be graphed using Graph Pad Prism Software.
(0192 0193 Lungs will be harvested from eight animals per treatment group. Half of each lung will be fixed with 10% formaldehyde neutral buffer solution for 24 hours, dehy drated in a graded ethanol series, embedded in paraffin, and sliced at 5 um. Paraffin sections will be stained with hema toxylin-eosin (HE) and Masson for histopathologic analysis. The remaining lung half will be Snap frozen and processed for human cell detection (see below).
0194
(0195 Total RNA will be isolated from all snap-frozen lung tissue by Asuragen, Inc., according to the company's standard operating procedures. The purity and quantity of total RNA samples will be determined by absorbance read
Histology
Human Cell Detection Jun. 24, 2010 ings at 260 and 280 nm using a NanoDrop ND-1000 UV spectrophotometer. RNA integrity will be evaluated using an Agilent Bioanalyzer.
(0196. Human-specific assays for GAPDH mRNA (Hs99999905 ml GAPDH) will be used to estimate the number of hUTC within mouse lung tissue. Samples for quantitative RT-PCR (qRT-PCR) analysis using single-tube TaqMan(R) Assays (Applied Biosystems) will be processed by Asuragen, Inc., according to the company's standard operat ing procedures. Dilutions of total RNA will be reverse tran scribed using the Tag Man(R) High Capacity cDNA Synthesis Kit (Applied BioSystems) according to the manufacturer's instructions and in a total reaction volume of 20 microliters per dilution. 50 ng input cloNA will then be analyzed by PCR. All amplifications will be performed in triplicate on a vali dated ABI 7500 real-time thermocycler. Following incuba tion at 95°C. for 10 minutes, samples will be amplified in 40 cycles of 95°C. for 15 seconds, then 60° C. for 1 minute.
Example 4 Pulmonary Protective Efficacy in a Rodent Model of
Elastase Induced Emphysema 0197) This study will demonstrate the efficacy of intrave nously administered hUTC in treating, ameliorating and/or preventing elastase-induced emphysema in a rodent model. 0198 C57BL/6N mice or rats will be anesthetized with ether or intraperitoneal injection of ketamine (90 mg/kg) and xylazine (1 mg/kg) and given intranasal administration of 0.3 or 1.2 units of porcine pancreatic elastase (Sigma-Aldrich, St. Louis, Mo., U.S.A). Control mice will receive intranasal administration of Saline alone.
0199 Two to twenty-four hours after elastase treatment, increasing concentrations of human umbilical tissue derived cells (hCTC) will be administered via tail vein injection. As described in Table 4 .1, 0.1x10, 1x10° or 3x10 hUTC, reconstituted in PBS vehicle, will be administered in a total volume of 200 ul. PBS vehicle, without hUTC will be admin istered in a similar fashion as in the hUTC treatment groups. Two weeks after vehicle or hUTC injections, the animals will be sacrificed to harvest lung tissue samples and bronchoal veolar lavage fluid (BALF), which will be stored at -70° C. prior to analyses. (0200 BALFAnalysis 0201 To prepare BALF, all animals will be euthanized and lungs will be lavaged once with 1.0 mL sterile PBS (Invitro gen) and the tubes will be placed on wet ice. The BALF will be centrifuged at 1000 rpm for 5 min and the supernatant fluid will be removed and used for further analysis. 0202 Cytokine/chemokine levels in both BALF and lung homogenate Supernatant will be determined using a mouse 22-multiplex bead kit (Millipore) following the manufactur er's protocol and analyzed using the BioRad Bioplex machine. The results will be graphed and analyzed using GraphPad Prism Software. 0203 BALF Total Protein Analysis 0204 To determine the total protein in each sample, cell free BALF will be analyzed using a BCA Protein Assay (Pierce). Analysis will be completed using the Softmax 4.0 program and data will be graphed using Graph Pad Prism Software.
0205 Histology 0206 Lung tissue samples will be fixed with 10% form aldehyde neutral buffer solution for 24 hours, dehydrated in a graded ethanol series, embedded in paraffin, and sliced at 5 um. Paraffin sections will be stained with hematoxolin-eosin (H&E) and Masson for histopathology analysis. 0207 Human Cell Detection 0208 Total RNA will be isolated from mouse tissues by Asuragen, Inc., according to the company's standard operat ing procedures. The purity and quantity of total RNA samples will be determined by absorbance readings at 260 and 280 nm using a NanoDrop ND-1000 UV spectrophotometer. RNA integrity will be evaluated using an Agilent Bioanalyzer. 0209 Human-specific assays for GAPDH mRNA (Hs99999905 ml GAPDH) will be used to estimate the number of hUTC within mouse lung tissue. Samples for quantitative RT-PCR (qRT-PCR) analysis using single-tube TaqMan(R) Assays (Applied Biosystems) will be processed by Asuragen, Inc., according to the company's standard operat ing procedures. Dilutions of total RNA will be reverse tran scribed using the Tag Man R High Capacity cDNA Synthesis Kit (Applied BioSystems) according to the manufacturer's instructions and in a total reaction volume of 20 microliters per dilution. 50 ng input cloNA will then be analyzed by PCR. All amplifications will be performed in triplicate on a vali dated ABI 7500 real-time thermocycler. Following incuba tion at 95°C. for 10 minutes, samples will be amplified in 40 cycles of 95°C. for 15 seconds, then 60° C. for 1 minute. Total number of hUTC within the mouse lungs will be estimated based on a standard curve generated by analyzing known amounts of purified hUTC total RNA. 0210 BALF Total Protein 0211. A statistically significant decrease in BALF total protein concentration will be observed in hUTC treated ani mals compared to vehicle control treated animals. In addition, in is possible that significant neutrophil accumulation will be observed in PBS control animals but may be reduced in hUTC treatment groups.
0212 BALF Cytokine/Extracellular Matrix Protein Analysis 0213. A statistically significant decrease in profibrotic and/or proinflammatory cytokines will be observed in hUTC treated animals compared to vehicle control treated animals.
In addition, elastase will increase the content of ECM in bronchoalveolar lavage fluid, a marker for lung injury. These effects will be attenuated by hUTC treatment. 0220. After digestion, the tissues were centrifuged at 150xg for 5 minutes, the Supernatant was aspirated. The pellet was resuspended in 20 milliliters of growth medium (DMEM: Low glucose (Invitrogen), 15 percent (v/v) fetal bovine serum (FBS; defined fetal bovine serum; Lot #AND18475; Hyclone, Logan, Utah), 0.001% (v/v) 2-mercaptoethanol (Sigma), penicillin at 100 Units per milliliter, streptomycin at 100 micrograms per milliliter, and amphotericin B at 0.25 micrograms per milliliter (each from Invitrogen, Carlsbad, Calif.)). The cell suspension was filtered through a 70-micron nylon BDFALCON Cell Strainer (BDBiosciences, San Jose, Calif.). An additional 5 milliliters rinse comprising growth medium was passed through the strainer. The cell Suspension was then passed through a 40-micrometer nylon cell strainer (BD Biosciences, San Jose, Calif.) and chased with a rinse of an additional 5 milliliters of growth medium. 0221) The filtrate was resuspended in growth medium (to tal volume 50 milliliters) and centrifuged at 150xg for 5 minutes. The Supernatant was aspirated and the cells were resuspended in 50 milliliters of fresh growth medium. This process was repeated twice more. 0222. After the final centrifugation, Supernatant was aspi rated and the cell pellet was resuspended in 5 milliliters of fresh growth medium. The number of viable cells was deter mined using trypan blue staining Cells were then cultured understandard conditions. US 2010/0158877 A1 0223. The cells isolated from umbilical cord tissues were seeded at 5,000 cells/cm onto gelatin-coated T-75 flasks (Corning Inc., Corning, N.Y.) in growth medium. After two days, spent medium and unadhered cells were aspirated from the flasks. Adherent cells were washed with PBS three times to remove debris and blood-derived cells. Cells were then replenished with growth medium and allowed to grow to confluence (about 10 days from passage 0 to passage 1). On Subsequent passages (from passage 1 to 2 etc), cells reached sub-confluence (75-85 percent confluence) in 4-5 days. For these subsequent passages, cells were seeded at 5,000 cells/ cm. Cells were grown in a humidified incubator with 5 percent carbon dioxide at 37° C. 0224. In some experiments, cells were isolated from post partum tissues in DMEM-low glucose medium after diges tion with LIBERASE (2.5 milligrams per milliliter, Blendzyme 3: Roche Applied Sciences, Indianapolis, Ind.) and hyaluronidase (5 Units/milliliter, Sigma). Digestion of the tissue and isolation of the cells was as described for other protease digestions above, however, the LIBERASE/hyalu ronidase mixture was used instead of the CD or C:D:H enzyme mixture. Tissue digestion with LIBERASE resulted in the isolation of cell populations from postpartum tissues that expanded readily. 0225. Procedures were compared for isolating cells from the umbilical cord using differing enzyme combinations. Enzymes compared for digestion included: i) collagenase; ii) dispase; iii) hyaluronidase; iv) collagenase:dispase mixture (C:D); v) collagenase: hyaluronidase mixture (C:H); vi) dis pase:hyaluronidase mixture (DH); and vii) collagenase:dis pase:hyaluronidase mixture (CD:H). Differences in cell iso lation utilizing these different enzyme digestion conditions were observed (Table 5-1). 0226. Other attempts were made to isolate pools of cells from umbilical cord by different approaches. In one instance, umbilical cord was sliced and washed with growth medium to dislodge the blood clots and gelatinous material. The mixture of blood, gelatinous material and growth medium was col lected and centrifuged at 150xg. The pellet was resuspended and seeded onto gelatin coated flasks in growth medium. From these experiments a cell population was isolated that readily expanded. 0227 Cells have also been isolated from cord blood samples obtained from NDRI. The isolation protocol used was that of International Patent Application PCT/US2002/ 02.9971 by Ho et al. Samples (50 milliliterand 10.5 milliliters, respectively) of umbilical cord blood (NDRI, Philadelphia Pa.) were mixed with lysis buffer (filter-sterilized 155 milli molar ammonium chloride, 10 millimolar potassium bicar bonate, 0.1 millimolar EDTA buffered to pH 7.2 (all compo nents from Sigma, St. Louis, Mo.)). Cells were lysed at a ratio of 1:20 cord blood to lysis buffer. The resulting cell suspen sion was vortexed for 5 seconds, and incubated for 2 minutes at ambient temperature. The lysate was centrifuged (10 min utes at 200xg). The cell pellet was resuspended in Complete 20 Jun. 24, 2010 Minimal Essential Medium (Gibco, Carlsbad Calif.) contain ing 10 percent fetal bovine serum (Hyclone, Logan Utah), 4 millimolar glutamine (Mediatech Herndon, Va.), penicillin at 100 Units per milliliter and streptomycin at 100 micrograms per milliliter (Gibco, Carlsbad, Calif.) . The resuspended cells were centrifuged (10 minutes at 200xg), the Supernatant was aspirated, and the cell pellet was washed in complete medium. Cells were seeded directly into either T75 flasks (Corning, N.Y.), T75 laminin-coated flasks, or T175 fibronec tin-coated flasks (both Becton Dickinson, Bedford, Mass.). 0228 To determine whether cell populations could be iso lated under different conditions and expanded under a variety of conditions immediately after isolation, cells were digested in growth medium with or without 0.001 percent (v/v) 2-mer captoethanol (Sigma, St. Louis, Mo.) , using the enzyme com bination of C:D:H, according to the procedures provided above. All cells were grown in the presence of penicillin at 100 Units per milliliter and streptomycin at 100 micrograms per milliliter. Under all tested conditions cells attached and expanded well between passage 0 and 1 (Table 5 -2). Cells in conditions 5-8 and 13-16 were demonstrated to proliferate well up to 4 passages after seeding, at which point they were cryopreserved. 0229. The combination of C:D:H, provided the best cell yield following isolation, and generated cells that expanded for many more generations in culture than the other condi tions (Table 5-1 ). An expandable cell population was not attained using collagenase or hyaluronidase alone. No attempt was made to determine if this result is specific to the collagenase that was tested. 0230 Cells attached and expanded well between passage 0 and 1 under all conditions tested for enzyme digestion and growth (Table 5 -2). Cells in experimental conditions 5-8 and 13-16 proliferated well up to 4 passages after seeding, at which point they were cryopreserved. All cells were cryopre served for further analysis. , and doubling time (time in culture/popula tion doubling) were calculated. For the purposes of determin ing optimal cell expansion, the total cell yield perpassage was determined by multiplying the total yield for the previous passage by the expansion factor for each passage (i.e., expan sion factor-cells final/cells initial). 0240. The expansion potential of cells banked at passage 10 was also tested. A different set of conditions was used.
Normal dermal skin fibroblasts (cc-2509 lot #9F0844; Cam brex, Walkersville, Md.) and umbilicus-derived cells were tested. These cell populations had been banked at passage 10 previously, having been cultured at 5,000 cells/cm at each passage to that point. The effect of cell density on the cell populations following cell thaw at passage 10 was deter mined. Cells were thawed under standard conditions and counted using trypan blue staining Thawed cells were then seeded at 1,000 cells/cm in growth medium. Cells were grown under standard atmospheric conditions at 37°C. The growth medium was changed twice a week. Cells were pas saged as they reached about 85% confluence. The cells were Subsequently passaged until senescence, i.e., until they could not be expanded any further. Cells were trypsinized and counted at each passage. The cell yield, population doubling (ln (cells final/cells initial)/ln2) and doubling time (time in culture)/population doubling) were calculated. The total cell yield per passage was determined by multiplying total yield for the previous passage by the expansion factor for each passage (i.e., expansion factor cells final/cells initial).
0241 The expansion potential of freshly isolated umbili cus-derived cell cultures under low cell seeding conditions was tested in another experiment. Umbilicus-derived cells were isolated as described in a previous example. The cells were seeded at 1,000 cells/cm and passaged as described above until senescence. The cells were grown understandard atmospheric conditions at 37° C. The growth medium was changed twice per week. The cells were passaged as they reached about 85% confluence. At each passage, cells were trypsinized and counted by trypan blue staining The cell yield, population doubling (ln (cell final/cell initial)/ln2) and doubling time (time in culture/population doubling) were calculated for each passage. The total cell yield per passage was determined by multiplying the total yield for the previous passage by the expansion factor for each passage (i.e., expan sion factor cell final/cell initial). The cells were grown on gelatin and non-gelatin coated flasks.
0242. It has been demonstrated that low O. cell culture conditions can improve cell expansion in certain circum stances. (See, e.g., US2004.0005704). In order to determine if cell expansion of umbilicus-derived cells could be improved by altering cell culture conditions, cultures of umbilicus derived cells were grown in low oxygen conditions. The cells were seeded at 5,000 cells/cm in growth medium on gelatin coated flasks. The cells were initially cultured understandard atmospheric conditions through passage 5, at which point they were transferred to low oxygen (5% O2) culture condi tions.
0243
In other experiments cells were expanded on non coated, collagen-coated, fibronectin-coated, laminin-coated and matrigel-coated plates. Cultures have been demonstrated to expand well on these different matrices. 0244. Umbilicus-derived cells expanded for more than 40 passages generating cell yields of >1E17 cells in 60 days. In contrast, MSCs and fibroblasts senesced after <25 days and <60 days, respectively. Although both adipose-derived and omental cells expanded for almost 60 days, they generated total cell yields of 4.5E12 and 4.24E13 respectively. Thus, when seeded at 5,000 cells/cm under the experimental con ditions utilized, umbilicus-derived cells expanded much bet ter than the other cell types grown under the same conditions (Table 6 -1). 0245 Umbilicus-derived and fibroblast cells expanded for greater than 10 passages generating cell yields of 1E11 cells in 60 days (Table 6 -2). Under these conditions both the fibro blasts and the umbilicus-derived cell populations senesced after 80 days, completing >50 and >40 population doublings respectively.
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Jun. 24, 2010 0246 Cells expanded well under the reduced oxygen con ditions, however, culturing under low oxygen conditions does not appear to have a significant effect on cell expansion for postpartum-derived cells. These results are preliminary in the sense that any ultimate conclusions to be made regarding the effect of reduced oxygen would best be drawn from experi ments on growing cells in low oxygen from initial isolation. Standard atmospheric conditions have already proven Suc cessful for growing Sufficient numbers of cells, and low oxy gen culture is not required for the growth of postpartum derived cells.
0247 The current cell expansion conditions of growing isolated umbilicus-derived cells at densities of about 5,000 cells/cm, in growth medium on gelatin-coated or uncoated flasks, under standard atmospheric oxygen, are sufficient to generate large numbers of cells at passage 11. Furthermore, the data Suggests that the cells can be readily expanded using lower density culture conditions (e.g. 1,000 cells/cm).
Umbilicus-derived cell expansion in low oxygen conditions also facilitates cell expansion, although no incremental improvement in cell expansion potential has yet been observed when utilizing these conditions for growth. Pres ently, culturing umbilicus-derived cells understandard atmo spheric conditions is preferred for generating large pools of cells. However, when the culture conditions are altered, umbi licus-derived cell expansion can likewise be altered. This strategy may be used to enhance the proliferative and differ entiative capacity of these cell populations. 0248 Under the conditions utilized, while the expansion potential of MSC and adipose-derived cells is limited, umbi licus-derived cells expand readily to large numbers. were seeded at 5,000 cells/cm in gelatin-coated T75 flasks (Corning, Corning, N.Y.) . After 24 hours the medium was removed and the cells were washed with phosphate buffered saline (PBS) (Gibco, Carlsbad, Calif.) to remove residual medium. The medium was replaced with a modified growth medium (DMEM with D-valine (special order Gibco), 15% (v/v) dialyzed fetal bovine serum (Hyclone, Logan, UT), 0.001% (v/v) betamercaptoethanol (Sigma) , penicillin at 50 Units/milliliter and streptomycin at 50 milligrams/milliliter (Gibco)).
0251 Umbilicus-derived cells and fibroblast cells seeded in the D-valine-containing medium did not proliferate, unlike cells seeded in growth medium containing dialyzed serum. Fibroblasts cells changed morphologically, increasing in size and changing shape. All of the cells died and eventually detached from the flask surface after four weeks. Thus, it may be concluded that umbilical cord tissue-derived cells require L-valine for cell growth and to maintain long-term viability. L-valine is preferably not removed from the growth medium for umbilical cord tissue-derived cells.
Example 8
Karyotype Analysis of Cells 0252 Cell lines used in cell therapy are preferably homo geneous and free from any contaminating cell type. Human cells used in cell therapy should have a normal number (46) of chromosomes with normal structure. To identify umbilicus derived cell lines that are homogeneous and free from cells of non-umbilical tissue origin, karyotypes of cell samples were analyzed. 0253 UTC from postpartum tissue of a male neonate were cultured in growth media. Postpartum tissue from a male neonate (X,Y) was selected to allow distinction between neo natal-derived cells and maternal derived cells (XX). Cells were seeded at 5,000 cells per square centimeter in growth medium in a T25 flask (Corning, Corning, N.Y.) and expanded to 80% confluence. A T25 flask containing cells was filled to the neck with growth media. Samples were delivered to a clinical cytogenetics lab by courier (estimated lab to lab transport time is one hour). Chromosome analysis was performed by the Center for Human & Molecular Genet ics at the New Jersey Medical School, Newark, N.J. Cells were analyzed during metaphase when the chromosomes are best visualized. Of twenty cells in metaphase counted, five were analyzed for normal homogeneous karyotype number (two). A cell sample was characterized as homogeneous if two karyotypes were observed. A cell sample was character ized as heterogeneous if more than two karyotypes were observed. Additional metaphase cells were counted and ana lyzed when a heterogeneous karyotype number (four) was identified.
0254 All cell samples sent for chromosome analysis were interpreted by the cytogenetics laboratory staff as exhibiting a normal appearance. Three of the sixteen cell lines analyzed exhibited a heterogeneous phenotype (XX and XY) indicat ing the presence of cells derived from both neonatal and maternal origins (Table 8-1) . Each of the cell samples was characterized as homogeneous. (Table 8-1 ). Flow Cytometric Evaluation of Cell Surface Markers 0256 Characterization of cell surface proteins or "mark ers" by flow cytometry can be used to determine a cell line's identity. The consistency of expression can be determined from multiple donors, and in cells exposed to different pro cessing and culturing conditions. Postpartum cell lines iso lated from the umbilicus were characterized by flow cytom etry, providing a profile for the identification of these cell Humaniliac crest bone marrow was received from NDRI with patient consent. The marrow was processed according to the method outlined by Ho, et al. (WO03/025149). The marrow was mixed with lysis buffer (155 mM NHCl, 10 mM KHCO, and 0.1 mM EDTA, pH 7.2) at a ratio of 1 part bone marrow to 20 parts lysis buffer. The cell suspension was Vortexed, incubated for 2 minutes at ambient temperature, and centrifuged for 10 minutes at 500xg. The supernatant was discarded and the cell pellet was resuspended in Minimal Essential Medium-alpha (Invitrogen) supplemented with 10% (v/v) fetal bovine serum and 4 mM glutamine. The cells were centrifuged again and the cell pellet was resuspended in fresh medium. The viable mononuclear cells were counted using trypan blue exclusion (Sigma, St. Louis, Mo.) . The mononuclear cells were seeded in plastic tissue culture flasks at 5x10" cells/cm. The cells were incubated at 37° C. with 5% CO at either standard atmospheric O or at 5% O. Cells were cultured for 5 days without a media change. Media and non-adherent cells were removed after 5 days of culturing.
The adherent cells were maintained in culture.
0273 Actively growing cultures of cells were removed from the flasks with a cell scraper in cold phosphate buffered saline (PBS). The cells were centrifuged for 5 minutes at 300xg. The supernatant was removed and the cells were resuspended in fresh PBS and centrifuged again. The super natant was removed and the cell pellet was immediately fro
Zen and stored at -80° C. Cellular mRNA was extracted and transcribed into cDNA. The cDNA was then transcribed into cRNA and biotin-labeled. The biotin-labeled cRNA was hybridized with Affymetrix GENECHIP HG-U133A oligo nucleotide arrays (Affymetrix, Santa Clara, Calif.). The hybridizations and data collection were performed according to the manufacturer's specifications. Data analysis was per formed using "Significance Analysis of Microarrays" (SAM) version 1.21 computer software (Tusher, V. 0275. The data were evaluated by principle component analysis with SAM software as described above. The analysis revealed 290 genes that were expressed in different relative amounts in the cells tested. This analysis provided relative comparisons between the populations. 0276 Table 10 -2 shows the Euclidean distances that were calculated for the comparison of the cell pairs. The Euclidean distances were based on the comparison of the cells based on the 290 genes that were differentially expressed among the cell types. The Euclidean distance is inversely proportional to similarity between the expression of the 290 genes. (0277 Tables 10-3 , 10-4, and 10-5 show the expression of genes increased in placenta-derived cells (Table 10-3) , increased in umbilical cord-derived cells (Table 10 -4), and reduced in umbilical cord and placenta-derived cells (Table  10 -5). Tables 10-6 , 10-7, and 10-8 show the expression of genes increased in human fibroblasts (Table 10 -6), ICBM cells (Table 10-7) , and MSCs (Table 10-8) . Genes which were increased in expression in the ICBM-derived cells as compared to the other cell lines assayed. maltase-glucoamylase (alpha-glucosidase) nuclear receptor Subfamily 4, group A, member 2 V-fos FBJ murine osteosarcoma viral oncogene homolog hypothetical protein DC42 nuclear receptor Subfamily 4, group A, member 2 FBJ murine osteosarcoma viral oncogene homolog B WNT1 inducible signaling pathway protein 1 MCF.2 cell line derived transforming sequence potassium channel, Subfamily K, member 15 cartilage paired-class homeoprotein 1 Homo sapiens cDNA FLJ12232 fis, clone MAMMA1001206 Homo sapiens cDNA FLJ34668 fis, clone LIVER2000775 jun B proto-oncogene B-cell CLL/lymphoma 6 (zinc finger protein 51) Zinc finger protein 36, C3H type, homolog (mouse) 0279. The present example was performed to provide a molecular characterization of the cells derived from umbilical cord and placenta. This analysis included cells derived from three different umbilical cords and three different placentas. The study also included two different lines of dermal fibro blasts, three lines of mesenchymal stem cells, and three lines of iliac crest bone marrow cells. The mRNA that was expressed by these cells was analyzed on a GENECHIP oli gonucleotide array that contained oligonucleotide probes for 22,000 genes. 0280. The analysis revealed that transcripts for 290 genes were present in different amounts in these five different cell types. These genes include ten genes that are specifically increased in the placenta-derived cells and seven genes spe cifically increased in the umbilical cord-derived cells. Fifty four genes were found to have specifically lower expression levels in placenta-derived and umbilical cord tissue-derived cells.
0281. The expression of selected genes has been con firmed by PCR, as shown in Example 11. Postpartum-derived cells generally, and umbilical derived cells, in particular, have distinct gene expression profiles, for example, as compared to other human cells, such as the bone marrow-derived cells and fibroblasts tested here.
Example 11
Cell Markers 0282 Gene expression profiles of cells derived from human umbilical cord were compared with those of cells derived from other sources using an Affymetrix GENECHIP. Six "signature' genes were identified: oxidized LDL receptor 1, interleukin-8 (IL-8), renin, reticulon, chemokine receptor ligand 3 (CXC ligand 3), and granulocyte chemotactic protein 2 (GCP-2). These "signature' genes were expressed at rela tively high levels in umbilicus-derived cells. 0283. The procedures described in this example were con ducted to Verify the microarray data and compare data for gene and protein expression, as well as to establish a series of reliable assays for detection of unique identifiers for umbili cus-derived cells.
0284. Umbilicus-derived cells (four isolates), and normal human dermal fibroblasts (NHDF; neonatal and adult) were grown in growth medium in gelatin-coated T75 flasks. Mes enchymal stem cells (MSCs) were grown in mesenchymal stem cell growth Medium Bullet kit (MSCGM; Cambrex, Walkerville, Md.). 0285 For IL-8 experiments, cells were thawed from liquid nitrogen and plated in gelatin-coated flasks at 5,000 cells/ cm, grown for 48 hours in growth medium and then grown further for 8 hours in 10 milliliters of serum starvation medium DMEM low glucose (Gibco, Carlsbad, Calif.), penicillin (50 Units/milliliter), streptomycin (50 micrograms/ milliliter) (Gibco) and 0.1% (w/v) Bovine Serum Albumin (BSA; Sigma, St. Louis, Mo.). RNA was then extracted and the supernatants were centrifuged at 150xg for 5 minutes to remove cellular debris. Supernatants were frozen at -80° C. until ELISA analysis. 0286 Umbilical cord tissue-derived cells, as well as human fibroblasts derived from human neonatal foreskin, were cultured in growth medium in gelatin-coated T75 flasks. The cells were frozen at passage 11 in liquid nitrogen. The cells were thawed and transferred to 15 milliliter centrifuge tubes. After centrifugation at 150xg for 5 minutes, the super natant was discarded. Cells were resuspended in 4 milliliters culture medium and counted. The cells were grown in a 75 cm flask containing 15 milliliters of growth medium at 375, 000 cell/flask for 24 hours. The medium was changed to a serum starvation medium for 8 hours. The serum starvation medium was collected at the end of incubation, centrifuged at 14,000xg for 5 minutes and stored at -20°C. fuge tube and centrifuged at 150xg for 5 minutes. The super natant was removed and 1 milliliter growth medium was added to each tube to resuspend the cells. The cell number was determined with a hemocytometer. 0288 The amount of IL-8 secreted by the cells into the serum starvation medium was analyzed using ELISA assays (R&D Systems, Minneapolis, Minn.). All assays were con ducted according to the instructions provided by the manu facturer.
0289 RNA was extracted from confluent umbilical cord derived cells and fibroblasts, or for IL-8 expression, from cells treated as described above. Cells were lysed with 350 microliters buffer RLT containing beta-mercaptoethanol (Sigma, St. Louis, Mo.) according to the manufacturer's instructions (RNeasy Mini Kit; Qiagen, Valencia, Calif.) . RNA was extracted according to the manufacturer's instruc tions (RNeasy Mini Kit; Qiagen, Valencia, Calif.) and sub jected to DNase treatment (2.7 Units/sample) (Sigma St. Louis, Mo.) . RNA was eluted with 50 microliters DEPC treated water and stored at -80° C. RNA was also extracted from human umbilical cord. Tissue (30 milligrams) was Sus pended in 700 microliters of buffer RLT containing beta mercaptoethanol. Samples were mechanically homogenized and the RNA extraction proceeded according to manufactur er's specification. RNA was extracted with 50 microliters of DEPC-treated water and Stored at -80° C.
0290 RNA was reverse-transcribed using random hexam ers with the TaqMan reverse transcription reagents (Applied Biosystems, Foster City, Calif.) at 25°C. for 10 minutes, 37° C. for 60 minutes, and 95°C. for 10 minutes. Samples were stored at -20°C.
0291 Genes identified by cDNA microarray as uniquely regulated in umbilical cord cells (signature genes-including oxidized LDL receptor, interleukin-8, renin, and reticulon), were further investigated using real-time and conventional PCR. 0292 PCR was performed on cDNA samples using gene expression products sold under the tradename Assays-on Demand (Applied Biosystems) gene expression products. Oxidized LDL receptor (HsO0234028); renin (HsO0166915): reticulon (HsO0382515); CXC ligand 3 (HsO0171061): GCP-2 (HsO0605742); IL-8 (HsO017.4103); and GAPDH were mixed with cDNA and TaqMan Universal PCR master mix according to the manufacturer's instructions (Applied Biosystems) using a 7000 sequence detection system with ABI Prism 7000 SDS software (Applied Biosystems). Ther mal cycle conditions were initially 50° C. for 2 minutes and 95° C. for 10 minutes, followed by 40 cycles of 95°C. for 15 seconds and 60° C. for 1 minute. PCR data were analyzed according to manufacturer's specifications (User Bulletin #2 from Applied Biosystems for ABI Prism 7700 Sequence Detection System). 0293 Conventional PCR was performed using an ABI PRISM 7700 (Perkin Elmer Applied Biosystems, Boston, Mass.) to confirm the results from real-time PCR. PCR was performed using 2 microliters of cDNA solution (1x Taq polymerase (tradename AMPLITAQ GOLD) universal mix PCR reaction buffer (Applied Biosystems) and initial dena turation at 94°C. for 5 minutes. Amplification was optimized for each primer set. For IL-8, CXC ligand 3, and reticulon (94°C. for 15 seconds, 55° C. for 15 seconds and 72° C. for 30 seconds for 30 cycles); for renin (94° C. for 15 seconds, 53°C. for 15 seconds and 72°C. for 30 seconds for 38 cycles): for oxidized LDL receptor and GAPDH (94° C. for 15 sec onds, 55° C. for 15 seconds and 72° C. for 30 seconds for 33 cycles). Primers used for amplification are listed in Table   11 -1. Primer concentration in the final PCR reaction was 1 micromolar except for GAPDH which was 0.5 micromolar. GAPDH primers were the same as for real-time PCR, except that the manufacturer's TaqMan probe was not added to the final PCR reaction. Samples were separated on 2% (w/v) agarose gel and stained with ethidium bromide (Sigma, St. Louis, Mo.) . Images were captured on 667 film (Universal Twinpack, VWRInternational, South Plainfield, N.J.) using a fixed focal-length POLAROID camera (VWR International, South Plainfield, N.J.). conventional PCR and by sequencing PCR products. 0300. After growth in serum-free media, the conditioned media were examined for the presence of IL-8. The greatest amounts of IL-8 were detected in media in which umbilical cells had been grown (Table 11 -2). No IL-8 was detected in medium in which human dermal fibroblasts had been grown. Results of the ELISA assay for interleukin-8 (IL-8) performed on placenta-and umbilical cord-derived cells as well as human skinfibroblasts, Walues are presented here are picogram million cells, n = 2, sem, ND: Not Detected 0301 Cells derived from the human umbilical cord at pas sage 0 were probed for the production of selected proteins by immunocytochemical analysis. Immediately after isolation (passage 0), cells were fixed with 4% paraformaldehyde and exposed to antibodies for six proteins: von Willebrand Factor, CD34, cytokeratin 18, desmin, alpha-Smooth muscle actin, and vimentin. Umbilical cord-derived cells were positive for alpha-Smooth muscle actin and vimentin, with the staining pattern consistent through passage 11. 0302) The production of GROalpha, GCP-2, oxidized LDL receptor 1 and reticulon (NOGO-A) in umbilical cord derived cells at passage 11 was investigated by immunocy tochemistry. Umbilical cord-derived cells were GCP-2 posi tive, but GRO alpha production was not detected by this method. Furthermore, cells were NOGO-A positive. 0303 Accordance between gene expression levels mea sured by microarray and PCR (both real-time and conven tional) has been established for four genes: oxidized LDL receptor 1, renin, reticulon, and IL-8. The expression of these genes was differentially regulated at the mRNA level in umbilical cord-derived cells, with IL-8 also differentially regulated at the protein level. Differential expression of GCP-2 and CXC ligand 3 was not confirmed at the mRNA level. Although this result does not support data originally obtained from the microarray experiment, this may be due to a difference in the sensitivity of the methodologies.
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Jun. 24, 2010 0304 Cells derived from the human umbilical cord at pas sage 0 were probed for the expression of alpha-smooth muscle actin and vimentin, and were positive for both. The staining pattern was preserved through passage 11. 0305. In conclusion, the complete mRNA data at least partially verifies the data obtained from the microarray experiments.
Example 12
Immunohistochemical Characterization of Cellular Phenotypes 0306 The phenotypes of cells found within human umbilical cord tissue were analyzed by immunohistochemis try.
above control staining Representative images were captured using a digital color videocamera and ImagePro Software (Media Cybernetics, Carlsbad, Calif.). For triple-stained samples, each image was taken using only one emission filter at a time. Layered montages were then prepared using Adobe Photoshop software (Adobe, San Jose, Calif.). Surg. 2004; 77:812-8) ; tissue inhibitor of matrix metal loproteinase 1 (TIMP1); angiopoietin 2 (ANG2); platelet derived growth factor (PDGFbb); thrombopoietin (TPO); heparin-binding epidermal growth factor (HB-EGF); stro mal-derived factor 1 alpha (SDF-1alpha), neurotrophic/neu Jun. 24, 2010 roprotective activity (brain-derived neurotrophic factor (BDNF) (Cheng et al., Dev. Biol., 2003; 258:319-33) ; inter leukin-6 (IL-6); granulocyte chemotactic protein-2 (GCP-2); transforming growth factor beta2 (TGFbeta2)); or chemokine activity (macrophage inflammatory protein 1alpha (MIP1 alpha); macrophage inflammatory protein 1 beta (MI Plbeta); monocyte chemoattractant-1 (MCP-1); Rantes (regulated on activation, normal T cell expressed and secreted): 1309; thymus and activation-regulated chemokine (TARC); Eotaxin; macrophage-derived chemokine (MDC); and (IL-8). 0314 Cells derived from umbilical cord, as well as human fibroblasts derived from human neonatal foreskin, were cul tured in growth medium on gelatin-coated T75 flasks. Cells were cryopreserved at passage 11 and stored in liquid nitro gen. After thawing, growth medium was added to the cells, followed by transfer to a 15 milliliter centrifuge tube and centrifugation of the cells at 150xg for 5 minutes. The cell pellet was resuspended in 4 milliliters growth medium, and the cells were counted. Cells were seeded at 5,000 cells/cm in T75 flasks each containing 15 milliliters of growth medium, and cultured for 24hours. The medium was changed to a serum-free medium (DMEM-low glucose (Gibco), 0.1% (w/v) bovine serum albumin (Sigma) , penicillin (50 Units/ milliliter) and streptomycin (50 micrograms/milliliter, Gibco)) for 8 hours. Conditioned serum-free medium was collected at the end of incubation by centrifugation at 14,000xg for 5 minutes and stored at -20°C. 0315. To estimate the number of cells in each flask, the cells were washed with phosphate-buffered saline (PBS) and detached using 2 milliliters trypsin/EDTA (Gibco). Trypsin activity was inhibited by addition of 8 milliliters growth medium. The cells were centrifuged at 150xg for 5 minutes. The Supernatant was removed, and the cells were resus pended in 1 milliliter Growth Medium. The cell number was estimated with a hemocytometer. 0316 Cells were grown at 37° C. in 5% carbon dioxide and atmospheric oxygen. The amount of MCP-1, IL-6, VEGF, SDF-1alpha, GCP-2, IL-8, and TGF-beta2 produced by each cell sample was determined by ELISA (R&D Sys tems, Minneapolis, Minn.). All assays were performed according to the manufacturer's instructions. Values pre sented are picograms per milliliter per million cells (n=2, sem). 0317 Chemokines (MIP1alpha, MIP1beta, MCP-1, Rantes, 1309, TARC, Eotaxin, MDC, IL8), BDNF, and angio genic factors (HGF, KGF, bFGF, VEGF, TIMP1, ANG2, PDGFbb, TPO, HB-EGF were measured using SearchLight Proteome Arrays (Pierce Biotechnology Inc.). The Proteome Arrays are multiplexed sandwich ELISAs for the quantitative measurement of two to sixteen proteins per well. The arrays are produced by spotting a 2x2, 3x3, or 4x4 pattern of four to sixteen different capture antibodies into each well of a 96-well plate. Following a sandwich ELISA procedure, the entire plate is imaged to capture the chemiluminescent signal generated at each spot within each well of the plate. The signal generated at each spot is proportional to the amount of target protein in the original standard or sample. 0318 MCP-1 and IL-6 were secreted by umbilicus-de rived PPDCs and dermal fibroblasts (Table 13-1). SDF-lalpha and GCP-2 were secreted by fibroblasts. GCP-2 and IL-8 were secreted by umbilicus-derived PPDCs. TGF-beta2 was not detected from either cell type by ELISA. Coumanset.al., Journal of Immunological Methods, 1999; 224: 185-196); and PD-L2 (Abbas & Lichtman, supra; Brown et. al., The Journal of Immunology, 2003 : 170: 1257 -1266 . To predict the extent to which postpartum umbilicus-derived cell lines elicit an immune response in vivo, the cell lines were tested in a one-way mixed lymphocyte reaction (MLR). 0322 Cells were cultured in growth medium in T75 flasks (Corning, Corning, N.Y.) coated with 2% gelatin (Sigma, St. Louis, Mo.) until confluent. 0323 Cells were washed in phosphate buffered saline (PBS) (Gibco, Carlsbad, Calif.) and detached with Trypsin/ EDTA (Gibco, Carlsbad, Mo.). Cells were harvested, centri fuged, and resuspended in 3% (v/v) FBS in PBS at a cell concentration of 1x107 per milliliter. Antibody (Table 14-1) US 2010/0158877 A1 was added to one hundred microliters of cell Suspension as per manufacturer's specifications and incubated in the dark for 30 minutes at 4°C. After incubation, cells were washed with PBS and centrifuged to remove unbound antibody. Cells were re-suspended in five hundred microliters of PBS and analyzed by flow cytometry using a FACSCalibur instrument (Becton Dickinson, San Jose, Calif.). 0324 Cryopreserved vials of passage 10 umbilicus-de rived PPDCs labeled as cell line "A" were packaged on dry ice and sent to CTBR (Senneville, Quebec) to conduct a mixed lymphocyte reaction using CTBRSOP no. CAC-031. Periph eral blood mononuclear cells (PBMCs) were collected from multiple male and female volunteer donors. Six human vol unteer blood donors were screened to identify a single allo geneic donor that exhibited a robust proliferation response in a mixed lymphocyte reaction with the other five blood donors. This donor was selected as the allogeneic positive control Jun. 24, 2010 donor. The remaining five blood donors were selected as recipients. Stimulator (donor) allogeneic PBMC, autologous PBMC, and postpartum cell lines were treated with mitomy cin C. Autologous and mitomycin C-treated Stimulator cells were added to responder (recipient) PBMCs and cultured for 0330. The present invention is not limited to the embodi 0327. Histograms of umbilical cord-derived cells ana lyzed by flow cytometry show negative expression of HLA DR, DP DQ, CD80, CD86, and B7-H2, as noted by fluores cence value consistent with the IgG control, indicating that umbilical cord-derived cell lines lack the cell surface mol ecules required to directly stimulate allogeneic PBMCs (e.g., CD4 T cells). 0328. The umbilical cells analyzed by flow cytometry were positive for expression of PD-L2, as reflected in the increase in fluorescence relative to the IgG control. The cells were negative for expression of CD178 and HLA-G, as noted by fluorescence values consistent with the IgG control. 0329. In the mixed lymphocyte reactions conducted with umbilical cell lines the average stimulation index ranged from 6.5 to 9, while that of the allogeneic positive controls ranged from 42.75 to 70. Umbilical cell lines did not express detect able amounts of the stimulating proteins HLA-DR, HLA-DP. HLA-DQ, CD80, CD86, and B7-H2, as measured by flow cytometry. Umbilical cell lines also did not express the immuno-modulating proteins HLA-G and CD178, but expression of PD-L2 was detected by flow cytometry. Allo geneic donor PBMCs contained antigen-presenting cells expressing HLA-DR, DQ, CD8, CD86, and B7-H2, thereby allowing for the stimulation of allogeneic lymphocytes. The absence on umbilicus-derived cells of antigen-presenting cell surface molecules required for the direct stimulation of naive CD4 T cells, as well as the presence of PD-L2, an immuno modulating protein, could account for the low stimulation index exhibited by these cells in a MLR as compared to allogeneic controls. ments described and exemplified above. The invention is capable of variation and modification within the scope of the appended claims.
Example 15 Assay for Telomerase Activity 0331 Telomerase functions to synthesize telomere repeats that serve to protect the integrity of chromosomes and to prolong the replicative life span of cells (Liu, K, et al., PNAS, 1999; 96:5147-5152) . Telomerase consists of two components, telomerase RNA template (hTERT) and telom erase reverse transcriptase (hTERT). Regulation of telom erase is determined by transcription of hTERT but not hTERT. Real-time polymerase chain reaction (PCR) for hTERT mRNA thus is an accepted method for determining telomerase activity of cells. 0332 Cell Isolation 0333 Real-time PCR experiments were performed to determine telomerase production of human umbilical cord tissue-derived cells. Human umbilical cord tissue-derived cells were prepared in accordance with Examples 5-7 and the examples set forth in U.S. application Ser. No. 10/877,012 (the 012 application). Generally, umbilical cords obtained from National Disease Research Interchange (Philadelphia, Pa.) following a normal delivery were washed to remove blood and debris and mechanically dissociated. The tissue was then incubated with digestion enzymes including colla genase, dispase and hyaluronidase in culture medium at 37° US 2010/0158877 A1 0334 Total RNA Isolation 0335 RNA was extracted from the cells using RNeasy.R. kit (Qiagen, Valencia, Ca.) . RNA was eluted with 50 micro liters DEPC-treated water and Stored at -80° C. RNA was reverse transcribed using random hexamers with the Taq Man(R) reverse transcription reagents (Applied Biosystems, Foster City, Calif.) at 25° C. for 10 minutes, 37° C. for 60 minutes and 95°C. for 10 minutes. Samples were stored at -20° C.
0336 Real-Time PCR 0337 PCR was performed on cNA samples using the Applied Biosystems Assays-On-DemandTM (also known as TaqMan R. Gene Expression Assays) according to the manu facturer's specifications (Applied Biosystems). This com mercial kit is widely used to assay for telomerase in human cells. Briefly, hTERT (human telomerase gene) (HsOO162669) and human GAPDH (an internal control) were mixed with cDNA and TaqMan(R) Universal PCR master mix using a 7000 sequence detection system with ABI prism 7000 SDS software (Applied Biosystems). Thermal cycle conditions were initially 50° C. for 2 min and 95°C. for 10 Jun. 24, 2010 min followed by 40 cycles of 95°C. for 15 sec and 60° C. for 1 min. PCR data was analyzed according to the manufactur er's specifications. 0338 Human umbilical cord tissue-derived cells (ATCC Accession No. PTA-6067), fibroblasts, and mesenchymal stem cells were assayed for hTERT and 18S RNA. As shown in Table 22 -1, hTERT, and hence telomerase, was not detected in human umbilical cord tissue-derived cells. What is claimed is:
1. A method of treating a patient having a lung disease, disorder or injury, the method comprising administering to the patient umbilical cord tissue-derived cells in an amount effective to treat the lung disease, disorder, or injury, and the damage caused thereby, wherein the umbilical cord tissue derived cells are derived from human umbilical cord tissue substantially free of blood are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a lung tissue.
2. The method of claim 1, wherein the lung disease, disor der or injury is, or is caused by, obstructive diseases or disor ders, restrictive diseases or disorders, or direct or indirect injuries.
3. A method of treating a subject having lung disease, said method comprising administering to the patient umbilical cord tissue-derived cells in an amount effective to treat lung disease, wherein said cells are derived from human umbilical cord tissue substantially free of blood and are capable of self-renewal and expansion in culture. 10. The method of claim 9, wherein the agent is an anti thrombogenic agent, an anti-inflammatory agent, an immu nosuppressive agent, an immunomodulatory agent, a pro angiogenic agent, or an antiapoptotic agent.
11. The method of claim 2, wherein the cells are adminis tered at the sites of the lung disease, disorder or injury.
12. The method of claim 1, wherein the umbilical cord tissue-derived cells are administered by injection, infusion, a device implanted in the patient, or by implantation of a matrix or scaffold containing the cells.
13. The method of claim 1, wherein the cells exerta trophic effect on the lung tissue of the patient.
14. The method of claim 1, wherein the cells exerta trophic effect on the vascular smooth muscle of the patient.
15. The method of claim 14, wherein the trophic effect is proliferation of the vascular smooth muscle cells. 17. The method of claim 16, wherein the trophic effect is proliferation of the vascular endothelial cells.
18. The method of claim 1, wherein the cells induce migra tion of vascular endothelial cells to the sites of the lung disease, disorder or injury.
19. The method of claim 1, wherein the cells induce migra tion of vascular endothelium progenitor cells to the sites of the lung disease, disorder or injury.
20. The method of claim 1, wherein the cells induce migra tion of vascular Smooth muscle cells to the sites of the lung disease, disorder or injury.
21. The method of claim 1, wherein the cells induce migra tion of vascular Smooth muscle progenitor cells to the sites of the lung disease, disorder or injury.
22. The method of claim 1, wherein the cells induce migra tion of pericytes to the sites of the lung disease, disorder or injury.
23. A pharmaceutical composition for treating a patient having a lung disease, disorder or injury, comprising a phar maceutically acceptable carrier and umbilical cord tissue derived cells in an amount effective to treat the lung disease, disorder or injury, wherein the umbilical cord tissue-derived cells are derived from human umbilical cord tissue substan tially free of blood are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a lung tissue. 24. A kit for treating a patient having a lung disease, dis order or injury, the kit comprising a pharmaceutically accept able carrier, a population of umbilical cord tissue-derived cells and instructions for using the kit in a method of treating the patient, wherein the umbilical cord tissue-derived cells are derived from human umbilical cord tissue substantially free of blood, are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a lung tissue. 25. A pharmaceutical composition for treating a patient having a lung disease, disorder or injury, which comprises a pharmaceutically acceptable carrier and a preparation made from umbilical cord tissue-derived cells, wherein the umbili cal cord tissue-derived cells are derived from human umbili cal cord tissue substantially free of blood, are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a lung tissue.
26. A kit for treating a patient having a lung disease, dis order or injury, the kit comprising the pharmaceutical com position of claim 25.
